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Abstract 
More than a million women worldwide are diagnosed with breast cancer every 
year and breast cancer is the most common cancer in women in the UK. Despite 
improvements in the treatment of breast cancer, it remains the second most 
common cause of death from cancer in women after lung.  Research into the 
aberrant molecular pathways which characterise neoplasia is necessary to 
highlight potential therapeutic targets with the aim of improving the survival of 
women with breast cancer. 
Rab25 is a member of the Rab superfamily of small GTPases, which are involved 
in the regulation of intracellular vesicular trafficking. A number of studies have 
suggested that dysregulation of Rab25 protein expression may be implicated in 
breast, ovarian and colorectal cancer. However, the published data are 
conflicting and further research is required to improve the understanding of the 
role of Rab25 in neoplasia. 
At the commencement of this project, there was no commercially available anti-
Rab25 antibody. The data presented here describe the affinity purification and 
validation of a rabbit polyclonal anti-Rab25 antibody suitable for use in Western 
blotting, immunofluorescence and immunohistochemistry. Furthermore, an 
immunohistochemical scoring system was devised and validated prior to the 
investigation of Rab25 expression in a large breast cancer cohort. 
The data presented here show that loss of Rab25 expression correlates with 
decreased breast cancer related survival of patients who have tumours which 
have also lost the expression of the oestrogen receptor. Furthermore, loss of 
Rab25 expression has maximal negative effect on the survival of patients with 
tumours which have lost both oestrogen and HER2 receptor expression.  
To investigate the effect of Rab25 knockdown in vitro, the MCF7 cell line was 
stably transfected with a short hairpin siRNA vector targeted against Rab25. 
Knockdown of Rab25 had no demonstrable effect on cellular proliferation or 
colony formation, but Rab25 knockdown cells can migrate to heal a scratch 
wound at a greater rate than cells transfected with a non-targeted control 
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vector.  Knockdown of Rab25 protein expression increases total surface and 
intracellular β1 integrin protein levels in MCF7 cells, but this increase is not as a 
result of increased transcription. 
The findings presented here suggest that loss of Rab25 in patients with ER 
negative/HER2 negative breast cancers confers a negative effect on survival of 
these patients. These findings are in direct contrast to previously reported work 
and suggest that perturbation of Rab25 levels, either increase or decrease, may 
be important in breast cancer. 
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1 Introduction 
Breast cancer remains a major health problem in the 21st century and more than 
a million women worldwide are diagnosed with breast cancer every year. Breast 
cancer is the most common cancer in women in the UK and in 2006 45,508 
women were diagnosed with the disease, which equates to around 125 women 
every day.  80% of breast cancers are diagnosed in women aged over 50. Breast 
cancer can also affect men and 314 men were diagnosed in the UK in 2006.  The 
incidence of breast cancer continues to rise and the incidence rates in the UK 
have increased by over 50% in the last twenty five years (1). 
Despite the rising incidence of breast cancer, more women are surviving the 
disease than ever before.  Survival rates have improved from 50% survival at 5 
years in the 1970’s to around 80% in the present day.  Survival rates are better 
the earlier the cancer is diagnosed and in women from the most affluent areas. 
The improvements seen in survival rates are due to mainly to advances in 
healthcare, such as earlier and more accurate detection of breast cancer and 
more effective treatment.  The NHS breast screening programme in England is 
responsible for the early detection of 10,000 breast cancers every year, saving 
an estimated 1,400 lives annually.  A recent French study demonstrated an 
improvement in survival from metastatic breast cancer from 27% to 44% over a 
14 year period, due in part to advances in chemotherapy and hormone therapy 
(2).   
Whilst these figures are encouraging, in the UK each year 12,000 women die 
from breast cancer and around 1300 of these deaths are in women under the age 
of 50.  Breast cancer is the second most common cause of death from cancer in 
women after lung (1). Traditional systemic treatments for breast cancer have 
included cytotoxic chemotherapy and hormonal manipulation, but more recently 
therapeutic agents have been developed that exploit the aberrant molecular 
pathways which characterise neoplasia, such as Trastuzumab which is a 
monoclonal antibody directed against the HER2 receptor.  Investigation of 
molecular processes which have been shown to be disregulated in cancer may 
lead to the development of novel therapies of clinical benefit, further improving 
the outcome for women with breast cancer.  
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1.1 Prognostic and predictive factors in early stage 
breast cancer 
1.1.1 Breast cancer is a heterogeneous group of diseases  
Whilst the term “breast cancer” is used to describe malignant tumours arising 
from the mammary gland, breast cancer is not a homogenous disease. Rather, 
breast cancer is a disease which encompasses a wide range of morphological, 
biochemical and clinical features which result in marked variation in response to 
treatment and survival from patient to patient.  The importance of classifying 
this group of diseases in order to tailor treatment plans and predict outcome for 
an individual patient has long been understood.  Historically the clinical features 
used to predict prognosis and inform treatment decisions have included age, size 
of tumour at presentation, involvement of axillary lymph nodes, histological 
grade of the tumour, hormone receptor status and HER-2 status and these are 
discussed in detail below. 
It is important to distinguish between prognostic factors and predictive factors. 
A prognostic factor can be defined as any measurement which provides 
information on disease outcome irrespective of treatment, and hence correlates 
with the natural history of the untreated disease.  A predictive marker is a 
marker which correlates to the responsiveness of a particular treatment and 
selects patients likely to benefit from one treatment over another. The 
Nottingham Prognostic Index (3)and Adjuvant Online (4)are the most commonly 
used algorithms used clinically to estimate the risk of disease recurrence and 
response to treatment respectively.  
 
It is becoming increasingly accepted that combining these two methods of 
estimating outcome may be useful in terms of defining residual risk, i.e. defining 
markers which predict disease outcome following adjuvant treatment. The 
Oncotype DX assay was developed in an attempt to quantify the residual risk of 
disease recurrence in patients with node negative, ER positive breast cancer, 
following adjuvant tamoxifen treatment. This assay uses the levels of expression 
of 16 outcome related genes and 5 reference genes to calculate a recurrence 
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score. The algorithm produced a continuous measure of risk, which has been 
used to identify 3 distinct risk groups; low risk (risk of distance recurrence 
<10%), intermediate risk (risk of distant recurrence 10-30%) and high risk (risk of 
recurrence >30%). (5) The algorithm has been shown to be predictive of the 
magnitude of benefit of chemotherapy in patient with ER positive, node negative 
disease. (6)    
1.1.2 Tumour size and grade 
The size of the tumour at presentation is an independent prognostic factor and 
also correlates with the number of involved axillary lymph node deposits (7). 
Survival decreases with increasing tumour size with overall 5 year survival rates 
of 86% in patients with tumours between 3 and 5 cm, 89% when the tumour is 
between 1 and 3 cm, and 99% in patients with tumours less than 1 cm in size.  
Tumour grade is assessed by classifying the mitotic index, differentiation and 
pleomorphism observed within the tumour. The system most widely used is the 
Scarff-Bloom-Richardson classification which scores each of these categories 
from 1 to 3 and the total of these scores defines the grade; Grade 1 (score 3 to 
5), Grade 2(score 6 to 7) and Grade 3 (score 8 to 9) (8). Tumour grade has been 
shown to have independent prognostic significance (9), however, it is primarily 
useful in making treatment decisions in patients who have small tumours and no 
involved lymph nodes. 
1.1.3 Axillary lymph node status 
The extent of involvement of the axillary nodes at the time of initial surgery is 
the most significant prognostic indicator in breast cancer. The extent of nodal 
involvement is categorised into four groups based on the data from the National 
Surgical Adjuvant Breast and Bowel Project. The groups are negative nodes, 1 to 
3 nodes positive, 4 to 9 nodes positive or 10 or more positive nodes. The five 
year survival for patients with node negative disease is 82.8% compared with 
28.4% in patients with the most extensive nodal involvement (5), and hence 
accurate staging of the axilla is of the utmost importance when considering the 
benefit of adjuvant treatment.   
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The classification of lymph node status in this way is reliant on a traditional 
axillary clearance. More recent surgical techniques have involved the sampling 
of the sentinel lymph node (10). The concept of sentinel node sampling is based 
upon the theory that if the first lymph node in the draining lymphatics (the 
sentinel node) does not contain metastatic disease (visible by hematoxylin and 
eosin staining) then it is unlikely that nodes further along the lymphatic chain 
will be involved.  
The advantage of sentinel node sampling is that it reduces the number of 
unnecessary axillary clearances and hence reduces the associated risk of 
lymphodema (11).  However, there remains some controversy in relation to the 
optimal assessment of the sentinel node and the importance of the presence of 
micrometastatic disease.  
The AJCC definition of micrometastatic disease has recently been changed. A 
micrometastasis is defined as a metastasis from 0.2mm (or >200 cells) to 2mm, 
with a macrometastasis defined as greater than 2mm in size. Clusters of cancer 
cells less than 0.2 mm or 200 cells are referred to as isolated tumour cell 
clusters. (12) 
A recent retrospective study demonstrated an increased risk of disease 
recurrence in patients with micrometastatic disease detected by 
immunohistochemistry compared with patients whose lymph nodes were truly 
negative (p=0.001) (13). However, a recently published prospective trial has 
shown no difference in the 8 year overall or disease free survival between 
patients with micrometastatic disease detected by immunohistochemistry and 
patients with node negative disease (14). It should be noted that both of these 
studies predate the new AJCC classification of micrometastatic disease. 
While the involvement of lymph nodes remains the most important prognostic 
indicator in breast cancer, further research is required to resolve the 
controversy surrounding the importance of micrometastatic disease. At the 
present time, decisions about the need for adjuvant therapy in patient with 
micrometastatic disease may need to be made on the basis of the other 
prognostic factors available to the clinician. 
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1.1.4 Lymphatic and vascular invasion  
Lymphatic and vascular invasion refers to the presence of tumour emboli in the 
surrounding lymphatic and blood vessels. In a large study of 1704 patients who 
did not receive adjuvant systemic therapies, lympho-vascular invasion was 
shown to be present in 22% of tumours and was of independent prognostic 
significance for local recurrence of tumour and breast cancer related survival 
(15).  Similar to tumour grade, the presence of lymphatic or vascular invasion is 
used to inform treatment decisions in patients with node negative disease with 
tumours of borderline size.  
1.1.5 Expression of the oestrogen receptor 
The oestrogen receptor exists in two main forms, ERα and ERβ, and is a steroid 
hormone nuclear receptor containing a highly conserved  DNA-binding domain 
(16).  The classically described mechanism by which binding of oestrogenic 
molecules to the receptor initiates gene transcription and cell proliferation 
involves binding of the activated receptor to oestrogen response elements (ERE) 
in the promoters of target genes (17). Treatment of breast cancer cells in vitro 
with physiological concentration of estradiol results in a marked increase in 
cellular proliferation and the converse is seen when the same cells are treated 
with tamoxifen, an oestrogen receptor antagonist (18).  
Expression of ER has long been known to be one of the most important  
prognostic factors in breast cancer (19, 20) and the clinical investigation of 
tamoxifen, a competitive antagonist of the oestrogen receptor in breast tissue, 
as an anti-cancer treatment in the 1960’s has arguably had the single biggest 
effect on survival of women with oestrogen positive breast cancer. In this regard 
ER is both a prognostic and predictive factor. The early trials of tamoxifen 
included oestrogen receptor positive and negative breast cancers and results of 
the efficacy of tamoxifen in breast cancer were often mixed, with effects noted 
on recurrence but not overall survival (21). Once the relevance of oestrogen 
receptor positivity was recognised and oestrogen receptor testing became 
routinely available in clinical practice, the effects of tamoxifen on survival 
became apparent. Meta analysis of the early tamoxifen trials showed a 26% 
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reduction in mortality with 5 years of adjuvant tamoxifen treatment in patients 
with ER positive disease (22). The underlying survival benefit of ER positivity per 
se, coupled with the beneficial effects of tamoxifen, means that women who 
have cancer which expresses the ER have the best chance of surviving their 
breast cancer in the shorter term. However, the risk of recurrence and death 
vary over time in patients with ER positive and ER negative disease. A recent 
metaanalysis of data generated from three consecutive clinical trials of 
chemotherapy showed that the risk of recurrence in ER negative patients was 
highest in the first two to three years after treatment, which then decreased 
dramatically with increasing time from diagnosis.  
In patients with ER positive disease, the risk of an event in the first few years 
after diagnosis was low, but the long term the hazards were slightly higher for 
patient with ER positive disease when compared with ER negative disease. (23) 
This demonstrates that, with the development of modern chemotherapeutic 
regimens, patients with ER negative cancer, who survive the first 5 years after 
diagnosis, have at least as good long term survival as patients with ER positive 
cancer. 
1.1.6 Expression of HER2 
The gene encoding HER2 has been shown to be overexpressed in 20-30% of breast 
cancers (24), and overexpression has been shown to be associated with 
significantly poorer clinical outcome when compared to cancers which do not 
overexpress HER2 (25), and this has been confirmed by the gene expression 
profiling studies, further discussed in Section 1.2. HER2 is a member of the type 
1 transmembrane tyrosine kinase receptor family which includes the closely 
related epidermal growth factor receptor (EGFR) (26). HER2 has been described 
as an “orphan” receptor as no high affinity ligand has been demonstrated (27).  
It forms homo- and heterodimers with the other members of the family, namely 
EGFR, HER3 and HER4 (28).  
A recent study has suggested that the higher levels of HER2 homodimers and a 
higher ratio of homodimers to HER2 total expression were significantly 
correlated with time to first recurrence in a cohort of breast cancer patients 
who had not been treated with adjuvant Trastuzumab. (29) Furthermore, 
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treatment of an in vitro model of MCF10A expressing a chimeric HER2 protein 
which could be induced to form either HER2 homodimers or heterodimers with 
EGFR or HER3 with Trastuzumab, inhibited homodimer-mediated cell growth but 
not heterodimer-mediated cell growth. (30) Further investigation of the clinical 
relevance of these observations is currently underway. 
Activation of the receptor by ligand binding results in the phosphorylation of 
discreet tyrosine sites located in the carboxyl terminus of the receptor which in 
turn leads to activation of multiple intracellular second messenger systems (31). 
Dysregulation of these second messenger systems, such as the Ras/MAP and 
PI3K/AKT pathways, have been shown to be implicated in carcinogenesis (32, 
33). The precise mechanism by which overexpression of HER exerts its effects 
are unknown, but the effect of increased activation of these pathways secondary 
to overexpression of HER2 upstream is thought to be the mechanism by which 
the HER2 exerts its effects on cancer cell growth and proliferation.  
 
1.1.6.1 Effect of HER2 overexpression on chemosensitivity 
Several studies have reported that the overexpression of HER2 may predict 
benefit from adjuvant chemotherapy. The widely accepted chemotherapy 
regimes for the adjuvant treatment of breast cancer in the last 20 years include  
either the combination of cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF) or doxorubicin and cyclophosphamide (AC) (34).  The choice of regime for 
a particular patient is usually based on the relative toxicity of the regimen and 
the duration of treatment, with AC being considered less toxic and shorter to 
administer.  
Retrospective analysis of a large adjuvant breast cancer trial has suggested that 
patients with tumours which express HER2 may derive preferential benefit from 
anthracycline-containing chemotherapy regimes, showing a relative risk 
reduction for death of 0.66 (p= 0.01) in favour of anthracyclines (35). A further 
study confirmed this trend but failed to reach statistical significance (36). In 
addition, there is evidence to suggest that patients with HER2 positive tumours 
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may be relatively resistant to CMF chemotherapy (37), but this finding has not 
been substantiated by further trials (38, 39). 
The addition of sequential taxane treatment following anthracycline-based 
chemotherapy has been shown to improve survival with a hazard reduction for 
death of 18% in favour of the addition of paclitaxel to AC (p=0.01) (40). An 
unplanned subgroup analysis suggested that this effect was greater in ER 
negative tumours compared with ER positive tumours. A further study assessing 
specifically the effect of paclitaxel on HER2 positive tumours showed a hazard 
ratio for death of 0.59 (p=0.01) in favour of the addition of paclitaxel in HER2 
positive tumours (41). On the findings from these studies, the standard 
treatment for HER2 positive disease is accepted to contain an anthracyline 
regime followed by sequential taxane. 
However, as HER2 overexpression has not been shown to confer improved 
chemosensitivity in in vitro systems, (42) research has considered the hypothesis 
that HER2 may be a surrogate for topoisomerase II alpha (Topo2A) expression. 
Topo2A has been shown to be a major target of anthracycline chemotherapy, 
(43) and co inhabits chromosome 17 with the HER2  gene. One question has 
therefore been “Are HER2 positive tumours more sensitive to anthracycline 
chemotherapy because of associated expression of Topo2A?”  
All of these studies are limited by the retrospective nature of the analysis, or 
unplanned subgroup analysis of small subgroup. The National Epirubicin Adjuvant 
Trial (NEAT) included a prospective analysis of predictive biomarkers of 
epirubicin sensitivity, which included HER2 and Topo2A and demonstrated no 
significant correlation between HER2 expression or Topo2A expression and 
survival benefit of epirubicin. However, in multivariate analyses, duplication of 
chromosome 17 centromere enumeration probe (Ch17CEP) correlated with 
improved relapse free and overall survival with anthracycline treatment. Given 
that HER2 and Topo2A are both expressed on chromosome 17, it is possible that 
the conflicting results in relation to sensitivity to anthracycline chemotherapy 
and HER2 expression are, in part, explained by this finding. Further investigation 
of Ch17CEP as a biomarker for anthracycline sensitivity is required. 
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1.1.6.2 Effect of HER2 overexpression on Tamoxifen sensitivity  
Both pre-clinical and clinical studies have suggested that the HER2 and ER 
pathways interact.  MCF7 cells that overexpress the HER2 receptor show 
decreased expression of the oestrogen receptor and increased resistance to 
tamoxifen treatment (44). A metaanalysis of clinical studies investigating the 
relationship between HER2 expression and tamoxifen resistance in metastatic 
breast cancer concluded that overexpression of HER2 does confer resistance to 
tamoxifen (45).  However, results in early breast cancer have been conflicting 
with a number of studies supporting the view that overexpression of HER2 
correlates with  tamoxifen resistance (46-48), with other studies failing to show 
any effect of HER2 expression on tamoxifen sensitivity (23). 
These studies have limitations that mean that the results should be interpreted 
with caution. All of the studies were retrospective and in some the subset 
analyses were small and unplanned. Furthermore, the methods used to assess 
HER2 status were not uniform and the reporting of HER2 status was not 
standardised at the time of these studies. The data presently available has not 
been considered strong enough to withhold tamoxifen treatment from patients 
with HER2 positive/ER positive breast cancer. 
1.1.6.3 The role of Trastuzumab in HER2 positive early breast cancer 
With the development of trastuzumab (Herceptin), a humanised monoclonal 
antibody against the Her2 receptor, Her2 positivity has now come to be regarded 
as a favourable predictive factor as opposed to a negative prognostic factor. 
There have been five large, multicentre randomised controlled trials 
investigating the adjuvant use of trastuzumab. The HERA trial, the largest of the 
trials, involved one year of adjuvant treatment with trastuzumab following 
chemotherapy in patients with HER2+ breast cancer. The results, which were 
published after only two years of follow up, demonstrated that trastuzumab 
reduced that rate of recurrence, particularly of distant metastases by 46% 
(hazard ratio 0.54 p=0.0001) (49).  The rate of cardiotoxicity , which has been 
linked to use of trastuzumab therapy, particularly in combination with 
anthracycline treatment (50), was shown to have a slightly increased incidence 
in the trastuzumab treated group, but the overall rates remained low at 0.5%.  
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The NSABP-B31, NCCTG N9531, BICGR 006 and FinHer trials reported similar 
improvements in disease recurrence to that seen in the HERA trial (51-53).  
There was some differences between the trials with respect to chemotherapy 
regimes and dosing schedules of trastuzumab, however the overwhelming effect 
of adjuvant trastuzumab on breast cancer recurrence was described as 
“revolutionary” in the editorial accompanying the publication of the HERA trial 
(54), and the outlook for patients whose cancers overexpress HER2 is therefore 
improving. 
1.1.7 Current prognostic and predictive factors have limitations 
Whilst the histopathological features described above have all been correlated 
to prognosis, they provide only very limited information on the underlying 
biology of the disease and provide no explanation for the very wide ranging 
difference in survival seen in patients displaying identical clinical 
characteristics. Two patients with identical clinical parameters can demonstrate 
very different clinical courses with respect to response to treatment, 
development or site of local or distant recurrence and survival.  
As a consequence of the limitations of these clinical predictive factors, it has 
become necessary to investigate further the underlying biological features of 
this diverse disease in an attempt to produce an improved taxonomy of breast 
cancer which is a more robust prognostic tool. The use of high throughput gene 
analysis has identified distinct subclasses of breast cancer which may be 
clinically useful. 
1.2 Breast cancer can be classified by gene expression 
profile  
Using gene expression profiling it has been shown that breast cancer can be 
subdivided into 4 main groups:- normal breast-like, luminal, HER2+ and basal-
like, with each group demonstrating  a distinctive molecular signature (55, 56). 
These studies used complementary DNA microarrays for 8102 human genes to 
provide a distinct molecular signature for each cancer sample. In total, 65 breast 
cancers were sampled, and the DNA signature of each sample was compared to 
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pooled RNA from 11 breast cancer cells lines as the reference sample. 
Hierarchical clustering was used to identify groups of tumours with similar 
patterns of over or under expression in relation to the reference dataset. 
Immunohistochemistry was performed for clinically relevant parameters such as 
ER and HER2 expression to corroborate the gene expression findings. 
The luminal group can be further subdivided into A, B and C subgroups and is 
characterised by high expression of many of the genes expressed by breast 
luminal cells, including the oestrogen receptor and genes associated with 
oestrogen receptor expression, such as GATA binding protein 3, oestrogen 
regulated LIV-1 and X-box binding protein 1 and also express cytokeratins 8 and 
18.  These tumours do not overexpress HER2 and this group accounts for around 
60-70% of breast cancers studied. 
The Her2+ group overexpress HER2 and other genes also involved in the 17q22.24 
amplicon. These tumours are generally ER negative and show low expression of 
the ER cluster genes described above. The basal-like group also show low 
expression of the ER cluster and Her2, but show high expression of cytokeratin 5 
and 17 and fatty acid binding protein, which are genes that are expressed in 
breast basal epithelial cells.   
The normal breast subtype has recently been reassessed and it has been 
suggested that this may not be a true subtype, rather that the analysed 
specimens contained a significant proportion of normal breast tissue which 
affected results (57). Further work is needed to substantiate this hypothesis and 
more recent papers have excluded the normal-like subgroup from analysis until 
this issue is clarified.  
Gene expression classification of tumour subtypes has clinical relevance as 
overall survival has been shown to be significantly different between subgroups 
(55, 58). Furthermore, there is a correlation between subgroup and response to 
neo-adjuvant chemotherapy (57).  Patients with luminal cancer have a highly 
significant increase in median survival when compared with the Her2+ and basal-
like subtypes. However, within the luminal subgroups there is a significant 
difference between the overall survival of patients with luminal subtype A, who 
have best survival outcome, and those with luminal subtypes B and C, suggesting 
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that the differences observed are not due entirely to the presence or absence of 
ER expression.   
The basal-like subgroup has been shown in many studies to account for a 
disproportionate number of breast cancer deaths. In one study overall 5 year 
survival for hormone receptor positive/HER2 receptor negative breast cancer 
patients was 94%,  hormone receptor positive/HER2 positive patients was 91% 
and hormone receptor negative/HER2 negative was 81% (59).  The gene 
expression profile analysis confirms that the basal –like cancers have the worst 
outlook and, coupled with the lack of a treatment target, this group of patients 
warrant further investigation.  
1.3 Basal-like and triple negative breast cancer 
1.3.1 Basal-like breast cancer cell resemble the cells of the 
normal myoepithelial layer of the breast. 
The basal-like subgroup defined in the gene expression studies outlined above 
accounts for approximately 15% of all breast cancers and the prevalence of 
basal-like cancer is significantly greater in premenopausal African American 
women (60). The genetic signature of this subgroup is the most homogeneous 
and in addition to the pattern of hormone receptor and HER2 negativity, these 
cancers frequently express high molecular weight cytokeratins CK5/6, CK17, in 
addition to vimentin and the epidermal growth factor receptor, which are 
usually found in myoepithelial cells of the normal breast (55).  
The normal breast epithelium is stratified and is comprised of two distinct layers 
the luminal, milk producing epithelium and the contractile myoepithelial layer.  
The current “stem cell” theory of breast cancer suggests that there may be early 
progenitor cells which can differentiate into either luminal epithelial cells or 
myoepithelial cells and that breast cancer heterogeneity may arise as a result of 
the neoplastic transformation of cells at any point along this differentiation 
spectrum. Experiments using mice have shown that an entire functioning 
mammary gland can be formed when a stem cell epithelial preparation is 
inoculated into a cleared mammary fat pad (61).  Cellular extracts from human 
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breast obtained from reduction mammoplasty specimens contain three distinct 
progenitor cell types, luminal cell restricted, myoepithelial cell restricted and 
bipotent cells which can produce colonies of both cell lineages when grown in 
vitro (62). Examination of the steroid hormone status of the mouse equivalent 
stem cell population has shown that these cells are ER, PR and HER2 negative, in 
keeping with the profile demonstrated by human basal-like breast cancer, 
suggesting the possibility that basal-like breast cancer may arise from such 
progenitor cells (63).  
While the current gene expression classification of breast cancer subdivides the 
disease into luminal, HER2+ and basal subtypes, there is evidence to suggest that 
breast cancer may arise from earlier progenitor cells which give rise to the 
differentiated components of the breast.  Strategies to target the stem cell 
population in human breast cancer, with the intention of improving clinical 
outcome, are currently the focus of research. 
1.3.2 Clinical identification of basal-like breast cancer 
The DNA microarray technology which has provided a useful tool in breast cancer 
research and provided the clinically relevant classification system described 
above is not readily available in everyday clinical pathology practice, nor can it 
be used in retrospective studies using formalin-fixed, paraffin embedded tissue.  
The lack of a robust and clinically usable assay to define basal-like breast cancer 
in the clinic has resulted in the use of the triple negative phenotype as a 
surrogate marker.  
Triple negative breast cancer is defined by a lack of expression of oestrogen, 
progesterone and HER2 receptors using standard immunohistochemical 
techniques and accounts for approximately 15% of all breast cancers (64, 65).  
Clinical studies confirm that the triple negative phenotype correlates with poor 
overall survival, shorter disease-free interval after primary treatment and 
increased incidence in premenopausal African – American women (60, 66).  
Because of the obvious similarities between triple negative breast cancer and 
basal-like breast cancer the two terms have become, somewhat erroneously, 
interchangeable.  
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However, while there is significant concordance between the triple negative 
phenotype and the basal-like gene signature, the two groups are not entirely 
synonymous.  A number of studies have shown that a significant proportion of 
triple negative tumours are not basal-like and vice versa. 7.3% of non-triple 
negative breast cancers express basal markers (67) and 16-44% of triple negative 
cancers are negative for EGFR, CK5/6 and CK14 (66, 68). Conversely, oestrogen 
receptor expression has been demonstrated in 15-45% of basal-like breast cancer 
and HER2 expression in 14% (54, 55).   
In an attempt to better identify basal-like breast cancers within the triple 
negative cohort, a “five marker” method has been proposed which includes 
immunohistochemistry for EGFR and CK5/6. When combining ER/PR and HER2 
negativity with EGFR and CK5/6 positivity, this five marker method has been 
shown to have a sensitivity of 76% and a specificity of 100% for the identification 
of basal-like tumours in cases identified by gene expression analysis (69).  
Furthermore, this five marker method has significantly better prognostic value 
than the triple negative phenotype and identifies as subgroup of high risk 
patients whose survival more closely mimics that seen in the basal-like group 
identified by gene expression (70).  
1.3.3 Improved identification of basal-like breast cancers in the 
triple negative subgroup is of clinical importance 
The triple negative subgroup is in itself a heterogeneous group of breast cancers. 
Further identification of the basal-like breast cancers within this group is 
important, as those cancers which are truly basal-like have the poorest prognosis 
and, at the present time, there is a lack of targeted therapies for this group of 
patients. In developing new treatments, particularly molecularly targeted 
treatments, it will be important to identify a molecularly distinct group of 
tumours which are likely to be sensitive to such treatments. The concern is that 
the beneficial effect of a targeted therapy can easily be lost if the study 
population is not accurately selected. This is illustrated by the original studies of 
gefitinib, an EGFR tyrosine kinase inhibitor, in lung cancer in which the patient 
population was unselected (71, 72). These trials did not show any benefit of the 
addition of gefitinib to standard chemotherapy, despite encouraging early phase 
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clinical trials.  Subsequent retrospective analysis has confirmed that a distinct 
subset of patients with EGFR mutations have an increased response to gefitinib 
(73).  
The gefitinib experience confirms that in the era of specifically targeted 
therapies, it is essential in clinical trials that the correct subgroup of patients is 
identified prospectively. With regard to breast cancer, and basal-like breast 
cancer in particular, the identification of novel markers and molecular pathways 
which have clinical significance in terms of outcome is important both in 
identifying potential therapeutic targets and in identifying the patients most 
likely to benefit from such treatments. 
1.4 The relationship between ER and PR expression in 
breast cancer.  
1.4.1 The synthesis of the progesterone receptor is under 
oestrogen control 
In the presence of oestrogen, progesterone receptors are synthesised in tissues 
such as the endometrium and breast which contain functional oestrogen 
receptors (74, 75).   This has led to the hypothesis that PR positivity is a more 
reliable indicator of response to hormonal treatment of breast cancer than ER 
status alone, as the presence of PR suggests that there is some oestrogenic 
activity  which may be abrogated by anti-oestrogen therapy, albeit that the ER 
receptor may not be detected by conventional laboratory techniques.  
Given the relationship between oestrogenic stimulation and progesterone 
receptor expression, the observation of ER negative/PR positive phenotype in a 
small minority of breast cancers has remained an anomaly. If progesterone 
receptor is indeed under the control of oestrogen activity, how is it possible for 
this phenotype to arise? 
There are a number of possibilities to explain this anomaly.  The standard 
diagnostic laboratory technique to assess hormone receptor status is 
immunohistochemistry and as such there is the potential for multiple variables 
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which contribute to a high false negative rate. The fixation process, choice of 
antibody and threshold for positivity  can all have an effect on the eventual 
immunohistochemical result (76, 77). These factors lead to a wide variation in 
the reporting of oestrogen receptor status. A study of inter-laboratory variation 
in diagnostic centres across the UK showed that 67% of the centres involved in 
the study failed to demonstrate oestrogen positivity in a confirmed low-
expressing oestrogen receptor positive tumour (78).  This significant false 
negative rate may provide some explanation for the persistence of the ER-
negative/PR-positive phenotype. 
More recently, the importance of external quality assurance provided by an 
independent reference agency has been recognised. In the UK this is provided by 
the United Kingdom National External Quality Assessment Service and provides a 
comprehensive external quality assessment service in many aspects of laboratory 
medicine, including steroid hormone and HER2 receptor testing in breast cancer. 
Membership of such a scheme has benefits with regard to the quality of testing 
with more experienced participants (defined as those with 6 or greater 
submissions for assessment) demonstrating the highest quality. (79) 
1.4.2 Does the ER-negative/PR-positive phenotype truly exist? 
The observed rate of tumours which are ER-negative/PR-positive is reported as 
1-5% of the total breast cancer population (80, 81).  Clinical outcome data 
suggests that in women with ER-negative disease, the disease-free interval and 
metastasis-free survival in ER-negative/PR-positive and ER-negative/PR negative 
is not significant at 10 years, but significantly different to those women with ER-
positive disease (81, 82). Given that these studies are relatively old, and that 
the methods used to determine hormone receptor status have since been 
refined, there is significant debate as to whether the ER-negative/PR-positive 
phenotype is a true pathological entity (83).  Current IHC methods, external 
quality assurance and a low threshold cut off, where any ER staining is reported 
as positive, have resulted in some studies reporting no evidence of ER-
negative/PR-positive breast cancers within the total breast cancer cohort (83). 
This suggests that knowledge of the PR receptor status in cancers which are 
otherwise ER and HER2 negative, may add very little in terms of determining the 
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basal nature of the tumour. Current thinking suggests that a cancer which is 
reported as ER negative is likely, by virtue of the relationship between ER and 
PR expression, to be also PR negative. Furthermore, the hierarchical clustering 
patterns, on which the subgroup classification is based, does not include 
progesterone receptor expression, suggesting that PR expression is of less 
importance in differentiating between the subgroups.  
1.5 The Rab protein family 
The Rab (Ras-related in brain) proteins constitute a diverse superfamily of over 
50 small GTPases which are involved in the regulation of intracellular vesicular 
trafficking (84).  Many of these Rab proteins have been shown to be involved in 
distinct stages of endocytic or exocytic membrane trafficking pathways, 
demonstrating a complex system in which Rab proteins act as the “couriers” 
enabling the right “package” to reach the correct intracellular “destination” 
(85).  
1.5.1 The Role of Rab proteins in vesicular transport 
Members of the Rab family are localised to discrete membrane compartments 
and the highly hydrophobic double geranylgeranylation at the C-terminal end of 
the proteins leads to their membrane association. As Rab proteins are GTPases, 
the proteins cycle between inactive GDP-bound forms and active GTP-bound 
forms. GDP dissociation inhibitor (GDI) binds the inactive GDP-bound form of Rab 
proteins and delivers the inactive proteins to the appropriate membrane 
compartment (86). Once at the correct membrane, GDI is displaced from the 
Rab protein by membrane associated GDI displacement factors (GDF) which 
facilitate the tethering of the Rab to the membrane.   
Once membrane associated, the Rab protein is activated by the exchange of GDP 
for GTP by a GDP/GTP exchange factor (GEF)(87, 88). Now in its active form, the 
Rab protein can interact with its downstream effectors. A number of Rab 
effectors have the ability to maintain the Rab protein in the activated GTP-
bound state, leading to the hypothesis that it may not be necessary for all Rab 
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proteins to complete the membrane release cycle after each GTP hydrolysis 
(89). Figure 1-1 shows a graphical representation of the cycling of Rab proteins.  
Individual Rab proteins are closely related to a specific compartment in the 
endocytic and exocytic vesicular trafficking pathways within the cell. For 
example, vesicular transport of cargo from the endoplasmic reticulum to the 
Golgi apparatus depends upon Rab1 and Rab2 (90, 91) and Rabs 6 and 8 are 
involved in transport of vesicles from the trans-Golgi network to the plasma 
membrane (92, 93).   In the endocytic pathway Rab 5 is associated with  early 
endosomes  and Rab7 with late endosomes (94).  
Rab proteins interact with a wide range of effectors such as motor proteins (95), 
elements of the vesicle fusion machinery (96) and tethering factors (97) to 
orchestrate a very tightly controlled cellular transport system in eukaryotic 
cells. 
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Figure 1-1 The Rab proteins cycle between two conformational states. 
GDP-bound forms are coupled to GDP-GTP dissociation inhibitor (GDI) and are delivered to the 
correct cellular compartment. Nucleotide exchange, catalysed by GDP-GTP exchange factor (GEF) 
results in the GTP-bound form which can interact with effector molecules. GTPase-activating 
protein (GAP) converts the GTP- to the GDP-bound form with the release of inorganic phosphate 
(Pi). 
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1.5.2 Rab proteins in polarised epithelial cells. 
Polarised epithelial cells, when organised into sheets of epithelial tissues, are 
responsible for both absorption and secretion in mammalian physiological 
systems.  These highly specialised functions rely on the specific directional 
processing of signals which are being received by the cell from both the apical 
and basolateral surfaces (98).  Epithelial cells maintain distinct apical and 
basolateral compartments and this intracellular conformation is reliant on 
regulated trafficking systems, of which the Rab proteins are part. 
Whilst the majority of Rab proteins appear to be ubiquitous, which is in keeping 
with the function of these proteins in the vesicular transport systems common to 
all cells, some Rabs, such as Rab25, exhibit a defined pattern of tissue 
distribution. Rab25 has been shown to be differentially expressed in polarised 
epithelial cells such as gastrointestinal mucosa, kidney and lung tissue (99). This 
pattern of distribution suggests that Rab25 may be involved in the regulation of 
aspects of trafficking which are unique to epithelial cells.  
1.5.3 The Rab11 subfamily 
The Rab proteins are further subdivided into groups which demonstrate 
approximately 40% homology with each other.  The Rab11 subfamily consists of 
Rab11a, Rab11b and Rab25.  Rab11a and Rab11b differ from each other in only 
the final 30 amino acids, but are coded for by different genes (100). They are 
ubiquitously expressed and are associated with the apical recycling system in 
polarised epithelial cells (101), and the plasma membrane recycling system in 
non-polarised cells (102).  
Rab25 was identified in the parietal cells of the gastric mucosa and shares 68% 
sequence homology with Rab11a, but differs in both the amino and carboxyl 
ends of the protein (Figure 1-2). The amino acid sequence of Rab25 shows a 
single amino acid substitution of leucine for glutamine in the G-3 WDTAGQE GTP-
binding domain (99). The WDTAGQE sequence is the consensus sequence which is 
shared by the majority of small GTP-binding proteins (103). The leucine to 
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glutamine substitution seen in Rab25 is also seen in Ras protein, where it 
conveys an transforming phenotype, preventing the hydrolysis of GTP, rendering 
the Ras protein constitutively active (104). Despite the presence of the 
WDTAGLE sequence in Rab25, recombinant Rab25 protein can bind GTP on a 
blot, suggesting that this sequence is of physiological significance in the normal 
functioning of this protein (99).  
In addition to the unusual WDTAGLE sequence, Rab25 contains a two amino acid 
difference in its effector domain.  The effector domain sequence has been the 
focus of Rab subfamily definition and hence it was not certain that Rab25 did 
indeed belong to the Rab11 family. However, the exon structure of  Rab11a, 
Rab11 b and Rab25 is very highly conserved , supporting the hypothesis that 
these three proteins are indeed part of the same gene family, albeit with 
specialised functions (105). 
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Figure 1-2 Amino acid sequence of Rab25, Rab11a and Rab11b. 
Deduced amino acid sequence obtained from Uniprot and aligned to show areas of homology. Sequences coloured aqua are homologous to all three proteins. Further 
areas of homology between Rab11a and Rab11b are shown in magenta
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1.6 Rab25 expression in cancer 
There is increasing evidence that alterations in Rab protein expression may be 
implicated in human disease. Of the Rab proteins, Rab25 is the most reported.  
1.6.1 Overexpression of Rab25 in ovarian cancer is associated 
with poor prognosis 
Rab25 is located on chromosome 1q22 and comparative genomic hybridization 
has revealed that gains in the chromosomal region 1q21-22 are associated with a 
drug resistant phenotype in ovarian cancer (106).  More recent work has 
concentrated on defining the regions of recurrent copy number increase in this 
amplicon. There are twenty two known genes and twelve hypothetical proteins 
contained within the region from position 152,377,895 to 153,495,551, based on 
the July 2003 human reference sequence. Eighteen candidate genes did not 
show a difference in expression levels between ovarian cancers and normal 
ovarian epithelium. The messenger RNA levels of the remaining sixteen 
candidates were assessed using quantitative PCR. Rab25 levels were increased in 
88.7% of ovarian cancers when compared with normal ovarian epithelium. Linear 
regression analysis confirmed a direct relationship between copy number and 
expression of Rab25 mRNA. Furthermore the expression of Rab25 has been shown 
to be closely correlated with clinical outcome with high levels of Rab25 
expression associated with decreased survival (107). 
More recent work investigating the relationship between androgen stimulation 
and the expression of Rab25 in ovarian cancer demonstrated that exposure of 
ovarian cancer cell lines to androgen resulted in only a marginal upregulation in 
Rab25 expression, which is of interest given that the antisense strand of the 
Rab25 gene contains an androgen response element (108). This study also 
investigated the relationship between Rab25 expression in ovarian cancer 
samples and overall survival, using immunohistochemistry with a commercially 
available Rab25 antibody, in a clinical cohort of 154 patients. No correlation was 
seen between Rab25 expression and overall survival in this cohort, which is in 
direct contrast with the findings of Cheng et al. outlined above (107).  
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Further work attempting to differentiate the genomic differences between the 
morphologically similar ovarian cancer, primary peritoneal cancer and diffuse 
malignant peritoneal mesothelioma  has shown that Rab25 is overexpressed in 
ovarian and primary peritoneal cancer compared with diffuse malignant 
peritoneal mesothelioma, suggesting that Rab25 may play a role in the 
pathogenesis of ovarian cancer (109). In addition, in vitro work investigating the 
effect of knockdown of Rab25 expression in the ovarian A2780 cancer cell line 
using a small interfering RNA expression vector has demonstrated decreased 
cellular proliferation rates, increased apoptosis and inhibition of tumour growth 
in xenograft models (110).  However, it should be noted that the A2780 cells 
used in the work described here have been shown by Western blotting and RT-
PCR not to express Rab25 and therefore the results of this study should be 
interpreted with caution.   
These data highlight that the clinical relevance of Rab25 expression in ovarian 
cancer is far from clear cut and further work to investigate the relationship 
between Rab25 expression and survival in ovarian cancer is needed. 
1.6.2 The relationship between Rab25 expression and survival   in 
breast cancer is unclear 
Approximately 50% of breast cancers contain an amplification in the 1q region, 
but in contrast to the specific 1q22 amplification seen in ovarian cancer, the 
amplification seen in breast cancer is broader and encompasses the majority of 
the 1q region (107).  Comparative gene hybridisation analysis revealed that 67% 
of breast cancers showed an increase in Rab25 expression of at least 1.7 fold 
that seen in normal breast tissue, suggesting that increased Rab25 expression is 
either an important initiating event in carcinogenesis, or a consequence of such.  
In this study, survival analysis of 109 patients was performed dividing the cohort 
into two groups – those with at least two-fold higher than normal Rab25 RNA 
expression and those with less than 2-fold higher than normal, as assessed by 
quantitative PCR.  When the cohort was divided in this way, those patients with 
high expression of Rab25 showed a decrease in overall survival and disease free 
survival, compared with low expressors.  In addition, Rab25 levels were an 
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independent prognostic factor when data were adjusted for tumour grade, 
tumour size and ER status. It should be noted that the breast cancer population 
used is this study included only patients with locally advanced disease at the 
time of diagnosis and included a higher than proportion of patients with a BRCA1 
mutation than would be expected in an unselected breast cancer population, 
and therefore caution should be exercised when extrapolating these results. 
Subsequent further comment on unpublished data from this study suggests that 
the expression of Rab25 may be related to the subtype of breast cancer, with ER 
positive tumours showing high levels of Rab25, basal tumours showing 
intermediate expression and metaplastic tumours showing low or absent 
expression.  These findings are in keeping with data which has shown that Rab25 
expression was detected in 6 nontumorigenic breast cell lines but lost in 4 out of 
9 tumorigenic breast cell lines, all of which had also lost expression of the 
oestrogen receptor. RT-PCR for Rab25 in breast cancer samples demonstrated 
loss of Rab25 in 83% of ER/PR negative breast cancer, compared with loss of 
Rab25 in only 8% of ER or PR positive tumours (111). 
Further work investigating the relationship between hormone receptor status 
and loss of Rab25 has shown that Rab25 expression, detected by RT-PCR, is lost 
in about 44% of breast cancers when compared with matched normal tissue. 69% 
of ER negative breast cancer samples showed loss of Rab25 compared with just 
21% of ER positive cancer specimens (p=0.005), suggesting preferential loss of 
Rab25 in ER negative tumours. Furthermore, immunohistochemical investigation 
of frozen sections of breast cancer confirmed reduced or absent Rab25 
expression in ER negative cancer samples, compared with those cancers which 
express the oestrogen receptor (112). 
There is an element of conflict between these data which requires further 
investigation. The data presented by Mills et al. suggests that overexpression of 
Rab25 is associated with poorer survival, irrespective of the hormone receptor 
status of the tumour, while the data presented by Rao et al. suggests that loss of 
Rab25 is far more common in ER negative tumours which, as described above, 
have a poorer clinical outcome than ER positive tumours. It is possible that the 
role of Rab25 is dependent on the subtype of breast cancer, and that 
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perturbations of Rab25 levels from the norm may have different effects in 
different subtypes of breast cancer.   
1.6.3 Loss of Rab25 is associated with poor survival in colon 
cancer 
Survival analysis of patients with colorectal cancer has shown that low gene 
expression of Rab25, described as Rab25 gene expression below the median for 
the cohort, correlates with significantly poorer overall survival when compared 
with high expression (113).  Furthermore, Rab25 expression was significantly 
decreased in primary colonic adenocarcinomas and lung and liver metastases 
compared with normal colon. The decrease in Rab25 was independent of the 
Dukes’ stage of the cancer, suggesting that loss of Rab25 occurs at an early stage 
in the progression of colorectal cancer. 
Further investigation into the effect of Rab25 loss in colorectal cancer has been 
undertaken utilizing mouse models of colorectal cancer. The adenomatous 
polyposis coli (Apc) min mouse contains a truncation of the Apc gene, which is 
the mouse homologue of the human adenomatous polyposis coli (APC) gene. Mice 
with the Apcmin gene develop adenomas within the gastrointestinal tract, 
predominately in the small intestine (114). 
Crossing the ApcMin/+ mouse with a Rab25 deficient mouse resulted in a 4 fold 
increase in tumour number throughout the intestine, but no increase in the 
invasive character of the lesions.  Mice which were heterozygous for Rab25 
showed an increase in intestinal tumour number which was intermediate 
between the wild type and deficient mice, suggesting haploinsufficiency. 
To assess the effect of Rab25 loss on the invasive potential of colonic tumours, 
the Rab25 deficient mouse model has been crossed with Smad3 heterozygous 
model. Homozygous loss of Smad3 in mice results in proximal colonic tumours, 
whereas the heterozygous model shows minimal pathology.  Smad3+/-, Rab25-/- 
mice developed large invasive lesions in 80% of mice, suggesting that Rab25 acts 
as a tumour suppressor in the colonic epithelium (113). 
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1.6.4 Rab25 in other cancer types 
With the advent of cDNA microarray technology, that allows the investigation of 
thousands of different genes simultaneously, many markers of carcinogenesis 
can be identified. Using this technology, Rab25 has been identified as being 
upregulated in testicular germ cell tumours (115) and transitional cell carcinoma 
of the bladder (116) when compared with their respective normal tissues. In lung 
cancer cell lines, Rab25 has been shown to be upregulated in squamous, large 
cell and small cell carcinoma cell lines when compared with a normal lung cell 
line (117). 
Conversely, loss of Rab25 expression, as demonstrated by 
immunohistochemistry, has been reported with increasing dysplasia in biopsy 
specimens of Barrett’s oesophagus (118). 
The role and effect of Rab25 dysregulation in epithelial cancers remains unclear, 
but preliminary evidence suggests that altered Rab25 expression is seen in many 
cancer types and further investigation to elucidate the mechanism by which 
Rab25 exerts its effects may prove useful in the development of novel anti-
cancer agents. 
1.7 Putative mechanisms of Rab25 effect in cancer 
1.7.1 Rab25 promotes invasive migration in 3D matrices 
Rab25 has been shown to interact specifically and directly with the β1 integrin 
cytoplasmic tail. In addition, A2780 ovarian cancer cells transiently expressing 
Rab25 invade fibronectin -containing 3D matrices to a significantly greater 
degree than control cells and this effect is dependent upon the interaction 
between Rab25, α5β1 integrin and fibronectin. Furthermore, the morphology of 
Rab25-expressing cells is altered and is characterised by the extension of long 
pseudopods, at the tip of which a discreet pool of actively cycling α5β1 integrin 
is maintained by Rab25  (119).  
Expression of Rab25 in A2780 cells slows the speed of migration of the cells, but 
increases the persistence of migration. Taken in combination with the finding of 
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elongated, persistent pseudopodial extension, these data give rise to the 
hypothesis that increased Rab25 expression promotes invasive migration by 
maintaining α5β1 integrin at the tip of the invading pseudopod. 
1.7.2 The effect of Rab25 on cell proliferation and apoptosis 
Exogenous expression of Rab25, by transfection with a Rab25 expression vector,  
results in increased colony forming activity and increased proliferation in a 
number of ovarian and breast cancer cell lines, which can be abrogated by RNAi 
transfection of Rab25. There is no significant change in cell cycle progression as 
a result of increased Rab25 expression, but cell survival is increased, suggesting 
a role for Rab25 in the regulation of cell survival (107). Furthermore, protein 
levels of BAK1 and BAX, which are part of the apoptotic signalling pathway, are 
decreased in the presence of increased Rab25 levels. This may be as a result of 
increased signalling through the PI3K-AKT pathway as higher levels of AKT 
phosphorylation are seen with increased expression of Rab25. 
Further evidence to support the hypothesis that Rab25 affects proliferation and 
cell survival is demonstrated by the increased rate of tumour growth in vivo of 
Rab25-transfected cells in mice xenograft models. 100% of mice injected with 
Rab25 expressing A2780 cells developed tumours compared with 50% of controls.  
In addition, the tumours formed were larger in the Rab25 expressing group and 
developed in a shorter time (107). 
Conversely, exogenous expression of Rab25 in two ER negative breast cancer cell 
lines reduces cell proliferation and anchorage independent growth in vitro. Cells 
are arrested in G2/M phase and there is a significant increase in early and late 
apoptosis compared with control cells (111, 112). As previously described, an in 
vivo mouse model of Rab25 loss in colon cancer demonstrates larger and more 
aggressive tumours, consistent with increased cellular proliferation and 
deceased apoptosis (113).  
The contradictory nature of these results suggests that the effect of Rab25 on 
cell proliferation and apoptosis may be dependent on the cellular context and 
further investigation is needed to elucidate the mechanisms by which Rab25 gain 
or loss exerts its effects. 
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1.7.3 Rab25 and growth factor receptor signalling 
Overexpression of the epidermal growth factor receptor is a commonly observed 
event in human cancer. Lung, oesophageal, gastric, colon, pancreatic and 
bladder cancer have all been shown to overexpress the EGF receptor, and 
overexpression correlates with poor survival (120-125). 
In A2780 cells overexpressing Rab25 the pattern of cell surface expression of 
EGFR following treatment with EGF differs from that seen in control cells, with 
higher surface expression of EGFR at 60 minutes in Rab25–expressing cells. In 
addition, AKT phosphorylation following exposure to EGF is increased in Rab25-
expressing cells compared with controls (126). 
The hypothesis that Rab25 may have a role in EGFR recycling is further 
supported by the finding that the presence of the αvβ3 integrin blocking agents 
osteopontin and cilengitide promote the association of Rab-coupling protein 
(RCP), α5β1 integrin and EGFR1 in a coprecipitatable complex and that this 
physical association is necessary for the effective recycling of EGFR1 under these 
conditions. Furthermore, this enhanced recycling of EGFR1 to the plasma 
membrane is associated with enhanced EGFR signalling as demonstrated by 
enhanced autophosphorylation of EGFR1 and activation of the PKB/AKT pathway 
(127).  
RCP, also known as Rab11 family interacting protein 1, is one of a family of four 
effector proteins which can associate with the Rab11 family members, including 
Rab25 (128). Whilst the physiological role of RCP is not entirely understood, it 
has been shown to be upregulated and positively associated with metastatic 
recurrence in breast cancer (129).  Furthermore, it has been shown that RCP and 
Rab25 mRNA levels are highly correlated in breast cancer samples, suggesting 
that there may be cooperation between these two genes in tumorigenesis (130).   
Colocalisation of Rab25 and RCP has not been investigated in the studies 
outlined above, but given the known interaction between the two and the strong 
evidence to support the individual interactions between Rab25 and RCP with the 
α5β1 integrin, it can be hypothesised that Rab25 is involved in the RCP/ α5β1 
integrin/EGFR complex which confers an invasive migratory phenotype to cancer 
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cells which may contribute to the poorer clinical outcome seen in patients with 
tumours which overexpress Rab25.  Figure 1-3 illustrates the hypothesised role 
of Rab25 in growth factor receptor signalling. 
 
Figure 1-3 Putative role of Rab25 in growth factor receptor signalling, proliferation and cell 
survival. 
Rab25 may have a role in the internalisation and trafficking of growth factor receptors from the cell 
surface to endosomes. Rab25 activates AKT and down-regulates BAK1 and BAX resulting in 
decreased apoptosis.  
From: Subramani and Alahari Molecular Cancer 2010 9:312. (131)
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1.8 The role of β1 integrin in breast cancer 
1.8.1 The extracellular environment plays a role in tumorigenesis 
The malignant transformation of normal cells to invasive cancer cells has been 
shown to involve multiple genetic events, altering growth and apoptotic 
pathways and providing a survival advantage to transformed cells. Increasingly, 
attention is being turned to the effect of the extracellular stromal environment 
on the behaviour of cancer cells, in an attempt to identify potential pathways 
that may be amenable to disruption by novel therapeutic agents. 
The discovery that, when exposed to medium containing basement membrane 
components, normal mammary and breast cancer cells grown in in vitro culture 
systems can recapitulate the structural and functional characteristics of these 
cells in vivo, highlighted the importance of the interaction between the 
extracellular matrix (ECM) and cells (132).  
The architecture of epithelial tissue is maintained by cell adhesion complexes 
which involve components of the extracellular matrix, cadherins, the actin 
cytoskeleton and integrins.  Epithelial tumours are characterised by disordered 
tissue structure and loss of cell polarity which results, in part, from 
perturbations in these interactions.   
β1 integrins are essential for the development and maintenance of polarised 
epithelial tissues (133, 134), and inactivation of the  β1 integrin gene in mice 
results in embryonic lethality (135). Furthermore, in the investigation of the role 
of the integrin family in breast cancer, the β1 integrin subfamily has emerged as 
potentially important in the initiation and maintenance of breast cancer (136). 
1.8.2 Increased β1 integrin is associated with decreased survival 
in breast cancer 
Immunohistochemical examination of a cohort of 250 invasive breast cancers for 
β1 integrin has demonstrated that patients with high expression of β1 integrin 
have a significantly decreased 5 year overall survival rate (45%) compared with 
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patients who have intermediate or low expression (85%).  In addition, β1 integrin 
expression significantly correlates with fibronectin expression (137).   
β1 integrin, when associated with one of the α integrins with which it forms a 
heterodimer,  binds to extracellular ligands which include fibronectin and 
laminin, expression of which have both been shown independently to correlate 
with poor survival in breast cancer (9, 138). However, in the study of β1 integrin 
expression in breast cancer described above, fibronectin was not an independent 
prognostic factor, suggesting that the interaction between β1 integrin and 
fibronectin may be of greater importance in the progression of breast cancer 
than the expression of fibronectin alone. Further evidence to support the 
hypothesis that the interaction between fibronectin and β1 integrin is of 
significance in cancer is demonstrated by the enhanced resistance of lung cancer 
to chemotherapy when the two are coexpressed (139).  
1.8.3 Disruption of β1 integrin function results in malignant 
reversion of breast cancer cells in vitro and in vivo 
When “normal” mammary epithelial cells are grown in a 3D culture of 
reconstituted basement membrane they form organised acinar structures which 
deposit a basement membrane, indicating polarisation of the acini (132). When a 
spontaneously tumorigenic cell line derived from this parent line is grown in a 
similar fashion the cells form loosely associated, disorganised colonies with no 
basement membrane.  In addition, β1 integrins are basally distributed in the 
normal acini, but randomly distributed in the tumour cell colonies with a large 
increase in total β1 integrin protein levels, but only a minor increase in cell 
surface levels (140). 
Treatment of the tumorigenic progeny with a β1 integrin blocking antibody 
results in the reversion of the malignant phenotype to the extent that after 12 
days incubation in a 3D matrix, colonies of the two cell types are 
morphologically indistinguishable and the tumour cells deposit a basement 
membrane. Incubation of the tumorigenic cell line with the β1 integrin blocking 
antibody prior to injection of the cells into nude mice results in reduced tumour 
size and number when compared with untreated cells, suggesting that once 
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“normalised” these cells can maintain a normal phenotype and their malignant 
potential is held in check by the normal tissue architecture. Furthermore, 
systemic treatment of nude mice bearing established xenografts of a number of 
different breast cancer cells lines with the anti- β1 integrin blocking antibody 
resulted in significantly less tumour growth over the 4 weeks of treatment 
compared with controls, with no obvious toxicity (141). These findings suggest 
that inhibition of β1 integrin function using monoclonal antibodies may be a 
useful therapeutic approach in the treatment of breast cancer.  
1.8.4 β1 integrin is required for the induction of mammary 
tumours in a mouse model of breast cancer 
As described above, germline deletion of the β1 integrin gene results in 
embryonic lethality in mice (135). Using the Cre/LoxP system,  β1 integrin 
expression in mammary tissue can be disrupted by breeding a conditional LoxP1 
β1 integrin mouse with a polyomavirus (PyV) middle T (MT)/Cre recombinase 
mouse using mouse mammary tumour virus (MMTV) as the transcriptional 
promoter (142). The MMVT PyV MT strain of mice is a well developed mouse 
model of breast cancer which recapitulates many aspects of human breast 
cancer progression, including atypical hyperplasia, adenocarcinomas and 
development of distant metastases. Mammary tumours appear with complete 
penetrance and female carriers develop palpable mammary tumours by week 5. 
By 3 months of age 90-100% of these animals will have developed pulmonary 
metastatic disease (142). 
Ablation of β1 integrin in MMTV PyV MT animals does not affect the mammary 
ductal outgrowth which occurs during puberty, and lactation and fertility are not 
affected by the deletion of β1 integrin from mammary tissue.  However, at 10 
weeks mammary tumours are not palpable in the β1 – deleted, β1LoxP1/LoxP1 
MMTV/Cre/PyV MT animals compared with β1LoxP1/wt MMTV/Cre/PyV MT control 
animals, which develop mammary tumours at the same rate and to the same 
extent as described for the parental MMTV/Cre/PyV MT strain as described 
above, with 100% of animals demonstrating palpable tumour burden at 10 weeks. 
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Furthermore, at 4 months of age β1LoxP1/LoxP1 MMTV/Cre/PyV MT animals develop 
palpable mammary tumours which retain expression of β1 intergrin, which is 
consistent with lack of excision of the β1LoxP1/LoxP1 alleles due to the absence of 
MMTV/Cre expression in these cells (136). This is in keeping with the reported 
stochastic expression of MMTV/Cre in this tumour model system.  
Taken together these data suggest that expression of β1 integrin is not necessary 
for the normal mammary gland development in mice, but is required for 
mammary tumour development in the MMTV/Cre/PyV MT breast cancer mouse 
model, further highlighting the potential therapeutic potential of  anti β1 
integrin agents in breast cancer. 
1.8.5 Clinical trials of the β1 integrin inhibitor Volociximab 
While there is growing evidence to suggest that β1 integrin expression on tumour 
cells is clinically relevant, the approach adopted with regard to β1 integrin 
inhibition has focused on inhibition of angiogenesis as the target, rather than 
direct targeting of tumour cells per se.  
As previously described, the β1 integrin forms a number of heterodimers with α 
integrin subunits. One of these heterodimers, the α5β1 integrin, has been 
extensively investigated as a potential therapeutic target in a number of solid 
tumours. 
The α5β1 integrin is the main fibronectin receptor and is upregulated in tumour 
vasculature and in proliferating vascular endothelial cells in vitro (143). 
Inhibition of α5β1 integrin function in in vitro and in vivo systems results in 
apoptosis of endothelial cells and inhibits angiogenesis (144).  Robust preclinical 
data to support the hypothesis that the α5β1 integrin may be a suitable 
therapeutic target has led to the development of Volociximab (M200), which has 
entered early phase clinical trials. 
Volociximab is a chimeric humanised anti-α5β1 integrin function blocking 
antibody and results of Phase II clinical trials in pancreatic and renal cancer and 
melanoma have been presented (145-147). These show that volociximab is well 
tolerated in a heavily pre-treated population and may be clinically efficacious. 
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Despite this promising early data, subsequent robust clinical efficacy data from 
Phase III trials have not yet emerged. There are a number of potential reasons 
for this, not least that the conventional efficacy measures used in clinical trials, 
namely response rate and survival, may not be adequate markers of efficacy for 
anti-angiogenic drugs, which do not have a direct effect on tumour cells and 
hence tumour volume. A method to quantify and monitor angiogenesis, either 
directly or using surrogate markers will be required, as it is likely that such 
agents will be cytostatic rather than cytotoxic.  In addition, combination 
therapies will have to be considered in a rational way in order to maximise 
benefit from integrin-based therapy. 
While the increased expression of β1 integrin has been shown to be associated 
with poorer clinical outcome in breast cancer, neither the nature of the integrin 
heterodimers involved, the factors which potentiate the increase nor the 
downstream effects of the increase are understood. If drugs which target 
intergrins are to be clinically successful, these mechanisms will need to be 
elucidated.  
1.9 Aims of this thesis 
Current prognostic markers for breast cancer are of value in informing treatment 
decisions with respect to adjuvant therapy following primary surgical removal of 
the tumour. However, current markers which can be routinely used in high 
throughput clinical laboratories have significant limitations. Much research 
activity is focussed on identifying other prognostic factors which may improve 
the ability to discriminate further those patients who might benefit from 
adjuvant treatments both currently available and in pre-clinical development. 
As has been discussed, the nature of the relationship between Rab25 expression 
and survival in breast cancer in unclear. There is some clinical data to support 
the hypothesis that increased expression of Rab25 is associated with a poorer 
clinical outcome in terms of survival, but conflicting data suggests that loss of 
Rab25 may be associated with ER negative tumours, which have a poorer clinical 
outcome than ER positive disease.  
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The aims of this project were to investigate if Rab25 expression can be reliably 
detected by immunohistochemistry in a clinical large cohort of breast cancer 
patients, and to ascertain if there is any relationship between Rab25 expression 
and breast cancer related survival. In order to undertake this investigation, it 
was first necessary to purify and validate a mouse polyclonal antibody for use in 
immunohistochemistry, and establish if a robust and reproducible 
immunohistochemical scoring system for Rab25 staining could be obtained. 
The currently available data gave rise to the hypothesis that Rab25 loss may be 
important in breast cancer, but the mechanism by which loss of Rab25 exerts its 
effect is unclear. To investigate the effect of Rab25 loss on breast cancer cell 
growth and motility, a Rab25 knockdown MCF7 breast cancer cell line was 
generated and characterised. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents, solutions and media 
Solution Ingredients Source 
AEBSF  Sigma 
Affi-gel 15  Bio-Rad 
Aprotinin  Sigma 
Bradford reagent  Sigma 
Coomassie Blue  Thermo Scientific 
Dulbecco’s Modified Eagle 
Medium (DMEM)  Gibco 
Fetal Bovine Serum (FBS)  Autogen Bioclear 
Glutathione Sepharose 
Beads  GE Healthcare 
Hybond-P  GE Healthcare 
IPTG  Melford Laboratories 
LB broth and agar  Beatson Institute Central Services 
Leupeptin  Sigma 
L-Glutamine  Gibco 
Lipofectamine  Invitrogen 
Milk  Marvel 
MOPS  Sigma 
Na Bicarbonate  Gibco 
NDLB Cell Lysis Buffer 
50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 1% Triton X-100, 5 
mM EGTA, 5 mM EDTA,10 nM 
Na Orthovanadate, 10 mM 
NaF, 0.5%, Igepal CA-630, 10 
µg/ml aprotinin, 2 mM 
AEBSF, 10µg/m leupeptin 
 
NuPAGE MOPS SDS Running 
Buffer (20X)  Invitrogen 
NuPAGE Sample Reducing 
Agent (10X)  Invitrogen 
Opti-MEM  Gibco 
PBS/EDTA (PE) PBS + 1 mM EDTA Beatson Institute Central Services 
Penicillin and ampicillin  Sigma 
Phosphate Buffered Saline 
(PBS) 
170 mM NaCl, 3.3 mM KCl, 
1.8 mM Na2HPO4, 10.6 mM 
Beatson Institute 
Central Services 
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H2PO4 
RPMI-1640 Medium  Gibco 
RTL buffer  Qiagen 
Streptavidin-HRP  GE Healthcare 
Streptomycin  Sigma 
TBS Tween (TBST) TBS + 0.1% Tween-20  
Transfer Buffer 50mM Tris, 40mM glycine, 0.04% SDS, 20% methanol 
Beatson Institute 
Central Services 
Tris  Sigma 
Tris Buffered Saline (TBS) 10 mM Tris-HCl, pH 7.4, 150 mM NaCl 
Beatson Institute 
Central Services 
Tris-acetate-EDTA (TAE) 40 mM Tris, 0.1% glacial acetic acid, 1 mM EDTA 
Beatson Institute 
Central Services 
Triton -X100  Perkin Elmer 
Trypsin 0.25% Trypsin in PE Gibco 
Vectashield-DAPI  Vector Laboratories 
 
2.1.2 Antibodies 
Antibody Dilution Source 
Western blotting 
Anti-Rab25 1:5000 In house 
Anti- β-actin 1:10 000 Cell Signalling Technology 
Anti-Rab11 1:1000 Cell Signalling Technology 
Anti-ITGβ1 1:500 BD Transduction Lab 
Anti-GST 1:10 000 Sigma 
Anti-GFP 1:10 000 Sigma 
Anti-mouse HRP-linked 1:5000 Cell Signalling Technology 
Anti-rabbit HRP-linked 1:5000 Cell Signalling Technology 
Immunohistochemistry 
Anti-Rab25 1:1000  
Immunoprecipitation 
Anti-ITGβ1  Chemicon 
Immunofluorescence 
Anti-Rab25 1:500  
Anti-haemagluttinin 1:250 Sigma 
Anti-mouse Cy3 1:100 Sigma  
Anti-rabbit Cy5 1:100 Sigma 
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2.1.3 Enzymes and kits 
Kit/Enzyme Application Source 
BglII Restriction enzyme Invitrogen 
Dako Envision Immunohistochemistry Dako 
HindII Restriction enzyme Invitrogen 
Improm II RT-PCR Promega 
Maxi-Prep Plasmid preparation Qiagen 
p-SUPER-GFP.neo  Expression vector Oligoengine 
Quantitect SYBR Green qPCR Qiagen 
RNeasy Isolation of RNA Qiagen 
 
2.1.4 Tissue culture plasticware 
Falcon tissue culture dishes and multi-well plates were used throughout.  
2.1.5 Tissues used for immunohistochemistry 
2.1.5.1 Mouse tissue 
Two virgin female Friend leukaemia virus B stain mice were culled by cervical 
dislocation and dissected. Portions of small intestine, colon, stomach, pancreas, 
spleen, liver, lung, kidney, muscle and brain were fixed in 10% neutral buffered 
formalin for 48hours. Tissues were then paraffin embedded, orientated and 
sectioned by Colin Nixon, Histology Service, Beatson Institute. 
2.1.5.2 Human tissue 
Commercial breast cancer tissue microarrays BR804 and BR1001 were purchased 
from  US Biomax. BR804 consisted of single cores of paired invasive breast 
cancer and matched normal adjacent tissue from 40 patients. BR1001 consisted 
of single cores of paired invasive breast cancer and matched lymph node 
metastases from 50 patients. 
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The West of Scotland Breast Cancer TMA consisted of a single 0.6mm tissue core 
sampled from each formalin-fixed paraffin embedded archival breast cancer 
specimen using a manual arrayer and mounted into a recipient paraffin block. 6 
TMA’s in total were constructed. Ethics approval was obtained from the West of 
Scotland Research Ethics Committee, title “Molecular profiling and clinical 
validation of breast cancer biological subtypes” REC reference number 
07/S0704/61. 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Origin of cell lines 
The cell lines used were kindly donated from individuals in the Beatson Institute 
of Cancer Research. A2780-Rab25, A2780-DNA3, SNU-601 and SNU-484 cells were 
a gift from Jim Norman, MCF10a cells were a gift from Adele Hannigan and MCF7 
cells were a gift from the group of Walter Kolch. 
2.2.1.2 Maintenance of cell lines 
A2780, SNU-484, SNU-601 cells were grown in RMI-1640 supplemented with 10% 
FBS, 2 mM glutamine, 10U/ml penicillin and 10µg/ml streptomycin.  MCF7 and 
MCF10a cells were grown in DMEM supplemented with 10% FBS, 2mM glutamine 
and 10U/ml penicillin and 10µg/ml streptomycin. Cells were maintained in a 
humidified 37°C /5% CO2 incubator.  To sub-culture adherent cells, the medium 
was removed by aspiration, the monolayer rinsed twice with PBS then 10% 
trypsin/PE solution was added until cell detachment.  Upon detachment the 
cells were resuspended in the appropriate growth medium and then transferred 
into tissue culture plates.  
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2.2.2 Protein production and purification 
2.2.2.1 Transformation of bacterial cells 
10-20ng of plasmid DNA was added to 50l of competent cells, mixed gently, and 
incubated on ice for 20 min.  The cells were then heat shocked by incubation at 
42 C for 45 sec in a water bath, and then for a further 2 min at 0 C.  450l of 
LB medium was then added, and the cells allowed to recover at 37 C, shaking 
for 1 hr.  50-200l of the transformation mix was spread evenly onto LB agar 
plates containing ampicillin, and the plates were incubated at 37 C overnight.   
Colonies from the plates were used to inoculate 3.5ml LB, and grown for 6 hours 
at 37 C. 0.5ml of the resulting bacterial culture was added to 100ml LB broth 
containing 100µg/ml ampicillin and incubated at 37 C overnight. Glycerol stocks 
(40 % glycerol, 60 % overnight culture) of all transformed plasmids were made, 
snap frozen, and stored at -80 C. 
2.2.2.2 Protein expression 
450ml of sterilised LB media, supplemented with 100ug/ml ampicillin, was 
inoculated with 50ml of the overnight culture described above and grown in an 
orbital shaker at 37oC for 1-2hr.  A 1ml sample of culture was removed to a plastic 
cuvette and the optical density measured at 600nm (OD600) against an LB media 
control.  Expression of the protein was induced with 0.25mM isopropyl-β-D-
thiogalactopyranoside (IPTG) when an OD600 of 0.5-0.6 was achieved.  An OD600 
at this level ensured that the culture was in the logarithmic phase, where bacteria 
will grow exponentially.  Expression of the target protein was undertaken for 2hr in 
an orbital shaker set at 37oC.  The cells were then harvested by centrifugation at 
1915g for 10min.  The cell pellet was resuspended in 10ml PBS containing 0.1% 
Triton and protease inhibitors.  The re-suspended cells were then frozen at –80oC 
and thawed on ice.  Lysozyme was added at a final concentration of 1mg/ml and 
the cell suspension subjected to sonication to achieve sufficient cell lysis and the 
subsequent cell debris was removed by centrifugation at 20235g for 15 min.    
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2.2.2.3 Purification 
Glutathione sepharose beads were prepared as per the manufacturer’s 
instruction. The cell supernatant was applied to the prepared beads and 
incubated end-over-end for 1hr 30 min at 4oC to bind the expressed fusion 
protein.  The beads were collected by centrifugation at 120g for 4 min at 4oC 
and washed three times with 1ml PBS 1% Triton followed by three washes in 1ml 
PBS.  The  protein was eluted from the glutathione beads with 250µl of 100mM 
NaCl, 50mM Tris-HCl, 3mg/ml glutathione; pH 8.0 by incubating end-over-end 
for 20min at 4oC.  This was repeated up to four times.  The eluted fractions were 
pooled and dialysed using Pierce® (Rockford, IL, U.S.A.) Slide-A-Lyser® dialysis 
cassettes against 5l of PBS pH 7.4. overnight 4oC.  The purified protein was 
frozen on dry ice, and stored in aliquots, at –80oC.  The expression time-course 
and final purification to homogeneity was analysed by SDS-PAGE and Coomassie® 
staining, described in Section 1.5.   
 
2.2.3 Antibody purification 
2.2.3.1 Preparation of Affi-gel column 
0.5ml Affi-gel 15 immunoaffinity support was washed twice in distilled water and 
incubated with 0.8mg of purified GST-Rab25 protein and 1ml 0.1M MOPS buffer 
pH 7.5 at 4oC and tumbled overnight. Then 50µl of glycine ethyl ester pH 8 was 
added to block any un-reacted groups on the Affi-gel column and tumbled for 1 
hr. The column was placed upright, allowed to settle and then washed twice 
with PBS, once with 20mM Na Citrate HCl pH 2.5 and twice more with PBS. The 
column was kept at 4oC until ready for use.   
2.2.3.2 Purification of antibody 
A 2ml aliquot of crude serum HF126B, from the terminal bleed of a rabbit 
inoculated with full-length Rab25 protein, was thawed on ice, added to the 
prepared Affi-gel column and tumbled overnight at 4oC. The column was then 
placed upright and allowed to settle for 30 min. The depleted serum was drained 
and the column washed five times with MOPS buffer. The antibody was eluted 
from the column in 5 fractions, using 0.5ml 20mM Na Citrate pH 2.5 per fraction. 
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The eluted fractions were neutralised with 35µl 1M Tris pH 9.0, combined and 
the protein content measured. The purified antibody was divided into 20µl 
aliquots and stored at -80oC. 
2.2.4 Protein extraction and analysis 
2.2.4.1 Preparation of cell lysates 
Protein extracts were made from cells when approximately 80% confluent.  Cells 
were washed twice with ice cold PBS then lysed with NDLB buffer containing the 
protease inhibitors aprotinin, leupeptin and AEBSF.  Lysed cells were scraped 
with a cell scraper and lysate transferred to a 1.5ml tube on ice for 15 min.  
Lysates were then centrifuged at 17949g at 4°C for 15 min to remove particulate 
matter, and cleared lysate was placed in a fresh 1.5ml tube.  Samples were then 
processed immediately, or frozen and stored at -20°C. 
2.2.4.2 Determination of protein concentration 
Protein concentrations were estimated using the Bradford colorimetric assay.  
Protein-containing solutions were mixed with Bradford assay solution and the 
absorbance at 595nm measured.  The protein concentration was then 
determined based on a standard curve derived from protein standards of known 
concentration. 
2.2.4.3 Coomassie® staining 
Polyacrylamide gels were removed from the pre-cast gel cassette and washed 
with sterile water to remove residual running buffer.  Coomassie® stain consisting 
of 1.25g Coomassie® Brilliant Blue R250 (omit for de-stain), 444ml methanol, 56ml 
acetic acid in a final volume of 1000ml sterile water was added to the gel with 
gentle shaking for 2hr at room temperature.  The Coomassie® stain was removed 
and replaced with de-stain.  De-stain removed all background staining with the 
Coomassie® stain remaining bound to the proteins resulting in the detection of all 
proteins present in the sample.  The gel was then washed with sterile water and 
kept hydrated by covering with Saran wrap.     
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2.2.4.4 Separation of proteins by polyacrylamide gel electrophoresis (SDS-
PAGE) 
The required amount of lysate to give typically 30µg protein was mixed with 5µl 
sample buffer and 2µl sample reducing agent, and diluted to a total volume of 
30µl with NDLB lysis buffer.  Samples were then heated at 95°C for five min, 
briefly centrifuged to collect the whole sample, and resolved on denaturing pre-
cast polyacrylamide gels by electrophoresis in gel tanks containing 1X running 
buffer at 120V for approximately 1 hr 30min. The separating gel contained 
between 8% and 12% acrylamide depending on the molecular weight of the 
protein to be visualised.  Molecular weight markers were run adjacent to the 
lysate samples. 
2.2.4.5 Western blotting 
Following electrophoresis, the proteins were transferred onto a PVDF membrane, 
while being buffered by 3mm filter paper saturated in NuPAGE® Transfer Buffer 
containing 20% methanol, in a BioRad semi-dry blotting apparatus at 10V for 1hr 
30 min. Following transfer, the membrane was blocked for 1hr at room 
temperature in 5% milk/TBS-T.  The primary antibody in 5% milk/TBS-T was then 
added overnight at 4°C.  The blots were then washed three times in TBS-T (5 
min each) and incubated with the appropriate horseradish peroxidase 
conjugated secondary antibodies for 1 hr.  The blots were again washed three 
times in TBS-T (15 min each).  All washes and incubations were performed with 
gentle agitation.  Proteins on membranes were visualised using an enhanced 
chemiluminescent detection reagent followed by autoradiography using Fuji 
Super RX medical X-ray film and a Kodak X-Omat 480 RA X-Ray processor.   
2.2.5 RT-PCR 
2.2.5.1 Isolation of RNA 
Total cellular RNA extracts were made from cells when approximately 80% 
confluent.  Cells were washed twice in ice-cold PBS (pH 7.4), residual PBS was 
allowed to drain and was aspirated. Cells were then lysed on ice, in 350µl of RLT 
buffer supplemented with β-mercaptoethanol (10µl per 1ml of the buffer). Cell 
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lysates were homogenised using QIAshredder columns and RNA was extracted 
and purified using the RNeasy kit, according to the manufacturer’s instructions. 
Residual genomic DNA was removed by incorporating an on-column DNAse I 
digestion step. RNA was eluted from the column in two sequential steps, each in 
30µl of sterile water.  
RNA concentration and purity was measured using a NanoDrop 
spectrophotometer. Samples with a concentration less than 0.6µg/µl were 
concentrated by centrifugation in SpeedVac concentrator for approximately 1.5 
hr. Those samples with an A260/280 measurement less than 1.7 were subjected to 
an additional clean-up step using the Qiagen RNeasy kit.  
RNA was then frozen and stored at -80ºC. 
2.2.5.2 cDNA generation from total RNA 
cDNA was synthesised from total RNA using Improm II kit according to the 
manufacturers instructions. 1µg of RNA was incubated with 0.5µg Oligo dT 
primer and the final reaction volume made up to 10µl with RNAse/DNAse-free 
water. The mixture was heated to 70ºC for 5 min in the Biorad DNA Engine 
Peltier Thermal Cycler and then chilled on ice for two min. 
0.5µl of RNAse/DNAse-free water, 4µl of 5x Reaction buffer, 3µl of 25mM MgCl2, 
1µl of 10mM dNTPs and 0.5µl of 40U/µl RNasin  were added to the RNA mixture, 
mixed gently and incubated at room temperature for 2 min. 1µl of Improm 
Reverse Transcriptase was then added, the sample was then incubated at 25ºC 
for 5 min and then at 42ºC for 1hr. The reaction was terminated by incubation at 
70ºC for 15 min and the sample was cooled to 4ºC and stored. 
2.2.5.3 PCR amplification 
Oligo Name Sequence (5’-3’) 
Rab25-#1Forward 
 
AGACCAATCTACTCTCCCGA 
 Rab25-#2Forward CCGGACCAATGCCATCACTC 
Rab25-#1Reverse  GACCCTGAGGGTGCTGTGAAC 
 Rab25-#2Reverse GAGGGTCCTAGTCTGTGAGG 
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Rab25-#3Reverse CGCAAAGATTTCTTTCAGGAC 
Rab11a-Forward CACCATATCCACCAGCAGGC 
 Rab11a-Reverse GCCCCACACATCATGAGCAC 
Rab11b-Forward CGCAGACCGCGCTGCCCACG 
 Rab11b-Reverse 
 
GGAGGACGTGCACGCACGCTG 
  
Primers for Rab25, Rab11a and Rab11b were designed with help from Marc 
Jones.  cDNA sequences were retrieved from NCBI , and suitable regions were 
chosen based on their size.  Sequences were examined visually, to exclude areas 
containing high GC content or those potentially likely to fold into hairpins.  
Regions with a good balance of bases were chosen and primer sequences were 
chosen to have a melting point between 60 and 70°C.  The proposed sequences 
were checked by performing a BLAST search. 
2µl of cDNA template, 5µl of 5x Reaction buffer, 1µl of 10mM each dNTP’s, 1µl 
each of 20µM forward and reverse primer and 0.2µl of Taq polymerse were made 
up to a final reaction volume of 50µl with RNAse/DNAse-free water. The cycling 
reaction was then performed in a Biorad DNA Engine Peltier Thermal Cycler, 
using the following conditions; 
95 C   5 min 
  95  C  30 s 
  55  C  30 s 
  72 C  30 s 
  72 C  10 min 
  4 C  until use 
 
2.2.5.4 DNA agarose gel electrophoresis 
DNA electrophoresis was carried out in 1% (w/v) electrophoresis grade agarose 
dissolved in 1xTAE buffer. Prior to gel solidification ethidium bromide was added 
at the final concentration of 0.5g/ml. DNA samples were diluted in 6x DNA 
loading dye before electrophoresis and loaded on to the gel alongside a suitable 
DNA ladder. Electrophoresis was conducted in 1xTAE buffer at 100 V for 1hr.  
DNA samples were visualized using UV transillumination. 
x30 
302
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2.2.5.5 qRT PCR 
All primers used to perform real time quantitative PCR were purchased from 
Qiagen as QuantiTect Primer Assay kits. The primer sequences are not disclosed 
by the manufacturer and therefore the corresponding catalogue numbers are 
listed below: 
Rab25 - Hs_RAB25_1_SG QuantiTect Primer Assay QT00087941 
β1-Integrin - Hs_ITGB1_1_SG QuantiTect Primer Assay QT00068124 
Β-actin Hs_ACTB_2_SG QuantiTect Primer Assay QT01680476 
GAPDH Hs_GAPDH_2_SG QuantiTect Primer Assay QT01192646 
Quantitative PCR was performed using the QuantiTect SYBR Green PCR kit on a 
BioRAD DNA Engine thermal cycler fitted with a Chromo4 Engine (Bio-Rad) and 
coupled to Opticon Monitor 3 software.  
The cDNA template was diluted 1:8 in sterile water and 8µl of the diluted cDNA 
was added to 10µl of 2x SYBR Green Mix and 2µl of 10x Primer Assay on a cooling 
block. The cycling reaction was performed using the following conditions: 
95C   15 min 
  95 C  30 s 
  60 C  30 s 
  72C  30 s 
  Plate read 
  72C  5 min 
  70-90C in 0.3ºC steps 
 
Data was extracted from the Opticon Monitor 3 software and the ΔΔC(t) method 
(Livak and Schmittgen 2001), or one that also incorporates amplification 
efficiencies (148), was used to calculate changes in gene expression with β-actin 
and GAPDH serving as reference genes. Each experiment was performed in 
triplicate and each replica incorporated three technical repeats. 
x40 
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2.2.6 Immunofluorescence 
Cells were plated on glass coverslips under standard culture conditions, at 
densities that produced a 50% confluent monolayer the following day.  Culture 
medium was removed from cells which were fixed in 4% formaldehyde for 15 min 
at room temperature. Cells were then permabilised in 0.2% Triton PBS and 
washed twice in PBS. After blocking with 100µl of 1% BSA PBS for 1 hr, coverslips 
were washed in PBS and then incubated with primary antibody for 1hr at room 
temperature. Following three washes in PBS, slides were incubated with 
secondary antibody for 1 hr at room temperature, washed three times in PBS and 
stained with FITC-phalloidin. Coverslips were washed a further three times in 
PBS and mounted using DAPI Vectashield. 
Cells were then examined using an Olympus BX51 confocal microscope.   
2.2.7 Immunohistochemistry 
2.2.7.1 Thrombin clot preparation 
Cells from two confluent 10cm plates were detached using trypsin and re-
suspended in 10ml culture medium. Cells were then pelleted by centrifugation 
at 106g for 5 min at 4°C. Following aspiration of the culture medium, the cell 
pellet was washed in 1ml PBS and centrifuged again. The pellet was then re-
suspended in 100µl PBS and 50µl of the cell suspension was added to 200µl of 
citrated bovine plasma.  50µl of thrombin solution was added to the plasma and 
cell and the resulting clot was fixed in 10% neutral buffered formalin and 
embedded in wax. 
2.2.7.2 Immunohistochemical staining 
Commercial or gifted paraffin embedded TMA blocks were sectioned by 
microtome prior to transfer to the Beatson Institute for Cancer Research. All 
other paraffin-embedded tissue was sectioned by the Beatson Institute for 
Cancer Research Histology Service. 
Immunohistochemistry was performed using the following protocol: 
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Procedure  Time  
Place sections in 60°C oven then cool 2 hr 
Place sections in Xylene 5 min 
Place sections in 100% Ethanol 1 min 
Place sections in 100% Ethanol 1 min 
Place sections in 70% Ethanol 1 min 
Wash sections in running tap water  
Heat induced epitope retrieval; 1 mM pH 8 EDTA at full 
pressure in microwaveable pressure cooker 4 min 
Leave sections in buffer to cool 20 min 
Wash sections in 10 mM Tris buffered saline Tween (TBST) pH 
7.5 5 min 
Block endogenous peroxidise (Dako EnVision) 5 min 
Wash sections in TBST 5 min 
Apply Rab25 Antibody (1:1000) 1 hr 
Wash sections in TBST 5 min 
Apply secondary antibody (Dako EnVision) 30 min 
Wash sections in TBST 5 min 
Apply 3.3’-Diaminobenzidine tetrahydrochloride 10 min 
Terminate reaction with deionised water  
Gills haematoxylin 2 min 
Wash sections in deionised water  
1% acid alcohol 3 dips 
Wash sections in deionised water  
Scotts tap water substitute 1 min 
Wash sections in deionised water  
Dehydrate, clear and mount  
 
2.2.8 Statistical analysis 
All statistical tests were performed using the Statistical Package for the Social 
Sceinces (SPSS) version 15 software, with the exception of power calculations 
which were performed using GPower 3.1 software. 
Test for normality of distribution of data was performed using the Kolmogorov-
Smirnov test.  
Pearson’s coefficient and the Wilcoxon Signed Ranks test were performed to 
calculate correlation in parametric and non-parametric data respectively. 
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Survival data were calculated using Kaplan Meier life table analysis and the 
relationship between prognostic factors was investigated using the Cox’s 
multiple regression analysis.  
The student’s t test was performed to investigate the difference between two 
means. 
2.2.9 Design of shRNA expression plasmid 
2.2.9.1 Oligonucleotide design 
The oligonucleotide hairpin was designed using the OligoEngine software. The 
hairpin was designed containing BglII and HindIII 5’ and 3’ ends respectively and 
the proposed sequence checked by performing a BLAST search. The hairpin 
sequence is shown in Figure 2.1. The  oligonucleotide strands were dissolved in 
nuclease – free water to a concentration of 3mg/ml and 1µl of each oligo was 
mixed with 48µl 100mM NaCl and 50mM HEPES pH 7.4.  
The mixture was incubated at 90°C for 4 min, 70°C for 10 min and then cooled 
slowly to 10°C. The annealed inserts were then kept at -20°C until needed. 
2.2.9.2 Preparation of vector 
The p-SUPER.neo+GFP vector was linearised by sequential digestion with HindII 
and BglII enzymes. 1µl of vector was incubated with 1µl of enzyme and 5µl of the 
appropriate buffer and 43µl of water. The digest was performed at 37°C and 
heat inactivated by raising the temperature to 80°C and the linearised vector 
stored at 4°C.  
The ligation reaction was performed using 2µl annealed oligonucleotide insert, 
1µl T4 ligase, 1µl T4 ligase buffer, 1µl linearised vector and 5µl of water and 
incubated overnight at room temperature.  1µl BglII was added for 30min at 
37°C to reduce the level of unligated background vector.  
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2.2.9.3 Sequencing 
The resulting construct was transformed into DH5α bacterial cells as described in 
section 1.3.1. Six colonies were grown up in a small scale culture and submitted 
to Beatson Technical Services for confirmatory DNA sequencing. Glycerol stocks 
of culture were prepared as described in section 1.3.1. 
2.2.9.4 Plasmid DNA isolation 
Following confirmation of the correct DNA sequence, a large scale culture was 
performed using a sample of glycerol stock of transformed cells in 500ml LB 
growth media containing ampicillin 100mg/ml.  This was transferred to a 2l flask 
of culture medium by means of a sterile pipette. The culture was incubated at 
37°C overnight with agitation. The cells were harvested the next day by 
centrifugation at 6000g for 15 min using the JA-14 rotor in the Beckman 
refrigerated centrifuge and the DNA extracted using the Wizard Maxi-prep kit 
according to the manufacturer’s instructions. 
 
2.2.10 Mammalian cell transfection with plasmid DNA 
The Lipofectamine method of transfection was used for transfection. Cells were 
plated in 6 well plates 24hr before transfection at a density which would ensure 
90-95% confluence on the day of transfection.  
10µl of Lipofectamine and 4µg of plasmid DNA were each diluted separately in 
250ml of Opti-MEM and incubated at room temperature for 15 min, then mixed 
together. The culture medium was aspirated from the cells and replaced with 
1.5ml Opti-MEM. 500µl of the DNA/Lipofectamine complex was added to each 
well and incubated at 37°C for 6 hr, following which the complex was removed 
and replaced with 2ml growth medium.  
24hr after transfection each 6 well plate was harvested and split into two 15cm 
plates and grown for a further 24 hr. Selective medium containing neomycin was 
added the following day.  
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Cells were allowed to grow for 10-14 days and colonies selected on the basis of 
GFP expression. Further sub-culturing of clones was performed and the effect of 
the vector on protein expression was determined by Western blotting as 
described in section 1.5. 
2.2.11 Cell growth assay 
2.2.11.1 Growth on plastic 
5x103 cells were plated per well of a 12 plate in triplicate. Four plates were 
prepared per cell line. 1ml of medium was added and cells were allowed to grow 
for eight days. Cells were counted every 2 days by trypsinising each well with 
350µl trypsin and neutralising the activity of trypsin with 50µl of foetal calf 
serum. Cells were counted using an automated cell counter.  
2.2.11.2 Growth in soft agar 
1.8% LMP agarose and 2x DMEM were warmed to 40°C. 1ml of agarose and 1ml of 
2xDMEM were mixed and plated per well of a six well plate and allowed to set at 
room temperature.  
0.9% LMP agarose and 2x DMEM were mixed in equal proportions. Cells were 
trypsinised and counted. 2x104 cells were mixed with 2ml of the 0.9% 
agarose/DMEM mixture and plated on top of the set 1.8% agarose layer and 
allowed to set.  
Cells were fed with growth medium three times weekly for 3 weeks and then 
counted. Total colony number per 6.25mm2 and total large colony number 
(colonies greater than 62.5µm in diameter) were counted in nine positions per 
well.  
2.2.11.3 Wound healing assay 
1x106 cells were plated in wells of a 6-well tissue culture plate at and allowed to 
grow in 2ml DMEM for 48 hr. Once confluent, one scratch was made in the 
monolayer using a sterile 10µl pipette tip and the media changed to remove de-
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adhered cells. Time lapse images were recorded of four fields per wound every 
15 min for 20 hr on a Nikon TE2000 microscope using a 10X objective.  Wound 
closure was quantified using Image J software. 
2.2.12 Cell surface labelling and immunoprecipitation 
Cells were plated and allowed to grow to 80% confluence. Plates were washed 
twice in PBS, incubated with 3ml 0.2mg/ml NHS-SS-Biotin in PBS for 30 min 
followed by two further washes with PBS. Cells were then lysed with NDLB 
containing protease inhibitors and the protein concentration measured. The 
protein concentration of the lysates was then corrected to ensure that the same 
amount of protein was added to each subsequent step. 50µl of each lysate was 
kept for Western blotting.  
Magnetic beads pre-coupled with sheep anti-mouse antibody were incubated 
with either 1.025µg of mouse anti-integrin β1 or 1.65μg of RG-16 per lysate. The 
beads were washed twice in 0.1% BSA PBS and re-suspended in 1ml PBS. The 
appropriate antibody was added and beads tumbled for 1hr at 4°C. 
The beads were then washed twice in 0.1% BSA PBS and re-suspended in PBS. 
450µl of prepared lysate was added to 50µl of prepared beads and tumbled for 2 
hr at 4°C. 
The beads were then washed three times in NDLB, re-suspended in 50µl of non-
reducing sample buffer and boiled for 5 min.  The supernatant was removed and 
Western blotting performed.  The resulting blot was incubated with 
streptavadin-HRP in 1% BSA overnight and proteins visualised using a 
chemiluminescent reagent. Western blots of reduced whole cell lysates were 
also performed to assess total protein levels and loading.   
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3 Affinity purification and validation of an anti-
Rab25 antibody 
3.1 Introduction 
To investigate the expression of Rab25 protein in archival clinical material, it 
was first necessary to obtain a reliable antibody that specifically recognised 
Rab25 and that was suitable for use in immunohistochemistry. As there is no 
effective commercial anti-Rab25 antibody currently available, it was necessary 
to generate an in-house antibody for this purpose. In previous work undertaken 
in the laboratory by Dominic White, a rabbit had been immunised with a purified 
preparation of full length human Rab25 protein and the resulting serum obtained 
from a terminal bleed was in storage at -20 °C. 
In general, crude antisera are unsuitable for use in immunohistochemistry owing 
to the large number of antibodies that recognise proteins other than the protein 
of interest.  The resulting background staining produced when crude antiserum is 
used in immunohistochemistry can entirely obscure the protein of interest to the 
extent that the staining patterns are meaningless. To obtain an anti-Rab25 
antibody with high specificity, it was therefore necessary to purify the crude 
anti-Rab25 antiserum by the process of affinity chromatography.    
Affinity chromatography is a well established purification technique in general 
laboratory use. The process of affinity purification relies upon the strong 
reversible association between biologically active proteins and their substrates 
and can be used to purify many classes of protein including antibodies (149). The 
crude serum containing the antibody to be purified is passed through a column 
of resin to which the corresponding antigen has been covalently bound.  The 
antibody recognises and binds competitively to the antigen, whilst all other 
proteins without affinity for the antigen pass through. The bound antibody can 
then be eluted and collected from the column by interruption of the non-
covalent interaction by a change in pH.  
Another requirement of an antibody used to test expression in clinical material is 
that it recognises the protein of interest specifically and does not detect other 
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closely related proteins. As described in detail in 1.5.3, Rab25 is a member of 
the Rab11 family of GTPases, the members of which are closely homologous. 
Given the close homology between Rab25 and Rab11a and Rab11b, it was 
necessary to establish that the Rab25 antibody could effectively distinguish 
Rab25 from the closely-related Rab11a and/or Rab11b. To test this, a bank of 
cells lines was assembled all of which were known to express Rab11a or b to 
varying degrees and had previously been shown to express Rab25 at the level of 
mRNA. 
This resource was used to assess the specificity of the affinity purified anti-
Rab25 antibody in Western blots and in an immunohistochemistry “pseudotissue” 
model. The “pseudotissue” is comprised of cells which are suspended in a small 
volume of plasma to which thrombin is added to form a clot. This clot is then 
fixed and embedded in paraffin and can then be subjected to the same 
immunohistochemical processes as archival clinical tissue.  This material 
provides a suitable substrate for optimisation of some of the experimental 
parameters for immunohistochemistry prior to investigation of Rab25 expression 
in whole tissues. 
The specificity of the anti-Rab25 antibody was also assessed in paraffin-
embedded mouse tissues with known expression levels of Rab25, and then by 
performing antibody pre-absorption experiments in tissues that expressed Rab25 
abundantly.  
3.2 Results 
3.2.1 The use of GST-Rab25 for affinity chromatography of the 
anti-Rab25 antibody 
A bacterial expression plasmid encoding a fusion protein of human Rab25 and 
GST under the control of a lac promoter was transformed into the BL21 stain of 
E. Coli. To induce expression of GST-Rab25 the transformed E. Coli were treated 
with IPTG and the bacteria were isolated by centrifugation and lysed. The 
expressed GST-Rab25 was the allowed to bind to a glutathione affinity resin and 
the bound protein eluted with glutathione and analysed by SDS-PAGE.  
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Coomassie blue staining and Western blotting of the column eluates indicated 
effective production of a protein corresponding to the predicted molecular 
weight for GST-Rab25, with an approximately equimolar concentration of a 
protein corresponding in molecular weight to GST. This band is presumed to 
indicate some cleavage of the GST-Rab25 protein during purification (Figure 3-
1). 
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Figure 3-1 Expression and purification of GST-Rab25 protein. 
A Coomassie blue staining of total lysate fraction and purified GST-Rab25 protein. 
B Western blotting of purified GST-Rab25 protein (n=2). 
 
 
The purified GST-Rab25 protein was covalently bound to an Affi-Gel column, 
incubated with the crude anti-Rab25 antiserum, and non-specifically attached 
material was removed by extensive washing.  The anti-Rab25 antibody was then 
eluted from the GST-Rab25 resin using a low pH wash. Aliquots of crude serum, 
depleted serum and eluted antibody were kept for use in Western blotting. 
Western blotting of lysates of NIH 3T3, A2780-DNA3 and A2780-Rab25 cells was 
performed to validate the purification process. NIH3T3 cells are a mouse embryo 
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fibroblast line, used here as a non-epithelial cell line control.  A2780-DNA3 and 
Rab25 cells are ovarian cancer cell lines which have been stably transfected with 
empty vector and HA-Rab25 respectively (Figure 3-2). The resulting purified 
antibody was then tested for its ability to recognise Rab25 using a number of 
different approaches. 
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Figure 3-2 Assessment of anti-Rab25 antibody purity. 
Western Blots were performed to assess the ability of affinity purified anti-Rab25 antibody to 
recognise Rab25 in NIH 3T3, A2780-DNA3 and A2780-Rab25 cell lysates. Blots were incubated 
with the indicated preparations of primary antibody (n=3). 
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3.2.2 Validation of anti-Rab25 antibody specificity  
3.2.2.1 Use of purified GFP-tagged Rab25 and Rab11a proteins to evaluate 
anti-Rab25 antibody specificity 
Purified protein preparations of GFP-tagged Rab25 and Rab11a were a gift from 
Patrick Caswell. Western blotting of these proteins using the anti-Rab25 
antibody confirmed that the antibody recognised a protein of the appropriate 
molecular weight. Indeed, the predicted molecular weights of GFP-Rab25 and 
GFP-Rab11a are both approximately 50 kDa (27kDa for GFP plus 24kDa for the 
GTPases) and the antibody clearly recognises GFP-Rab25 but not GFP-Rab11a 
(Figure 3-3).  
G
FP
G
FP
-R
25
50
50
G
FP
-R
11
a
Blot: Rab25
Blot: GFP
kDa
 
Figure 3-3 Assessment of anti-Rab25 antibody specificity.  
Western blots of purified GFP, GFP-Rab25 and GFP-Rab11a protein were incubated with anti-
Rab25 antibody (top panel) and anti-GFP antibody to assess gel loading (bottom panel) (n=3).  
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3.2.2.2 The use of Rab25 expressing and non-expressing cell lines to 
evaluate anti-Rab25 antibody specificity 
Following confirmation that the anti-Rab25 antibody recognised a protein of the 
appropriate size, it was necessary to confirm that the antibody would 
specifically recognise Rab25 in cell lines.  To do this, a panel of the following 
five human tumour cells lines was used: 
i) A2780-DNA3 cells, an ovarian cancer cell line which has been stably 
transfected with an empty vector. 
ii) A2780-Rab25 cells, an ovarian cancer cell line which has been stably 
transfected with an epitope-tagged Rab25, HA-Rab25. 
 iii) SNU-484 cells, a gastric cancer cell line which has been shown by RT-
 PCR not to express Rab25. 
 iv) SNU 601, a gastric cancer cell line which has been shown by RT-PCR to 
 endogenously express Rab25. 
 v) MCF10ACA1, a breast cancer cell line which has been shown by RT-PCR 
 to endogenously express Rab25. 
To confirm the expression of Rab11a, Rab11b and Rab25 in A2780-Rab25 and 
A2780-DNA3 cells at the mRNA level, RNA was extracted from these cell lines  
and cDNA synthesised from this. RT-PCR was carried out using 1µl of each cDNA 
reaction. PCR products were run on 1% agarose gel and visualised using the 
Genesnap gel documentation system. Details, including primer sequences can be 
found in Section 2.6. In addition, Western blotting of the same cell lysates was 
performed, using a Rab11 antibody which does not distinguish between the 
Rab11 a and b subtype. 
RT-PCR confirmed the presence of a band of the expected fragment size of 
Rab11a and Rab11b in both A2780-DNA3 and A2780-Rab25 cells, confirming the 
expression of Rab11a and Rab11b in these cells lines. Three potential candidate 
Rab25 RT-PCR primer pairs were designed and tested to determine the optimal 
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primers for further experimentation. Figure 3-4 A confirms that primer R25#2 is 
optimally designed to amplify Rab25 mRNA and that expression of Rab25 was 
limited to A2780-Rab25 cells. The primer pair R25#1 was minimally efficacious, 
and confirmed that the expression of Rab25 was limited to A2780-Rab25 cells, 
while the primer pair R25#3 did not amplify a product. The primer pairs R25#1 
and R25#3 were not used in further analysis.  Western blotting using a Rab11 
antibody confirmed the presence of a band consistent with the expected 
molecular weight of Rab11 in both cell lines although, as already stated, this 
antibody cannot distinguish between Rab11a and Rab11b. Furthermore, 
incubation of blots from the same lysates with the anti-Rab25 antibody produced 
a 25kDa band only in the A2780-Rab25 cells (Figure 3-4).  
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Figure 3-4 The anti-Rab25 antibody does not recognise Rab11 
A Reverse transcriptase PCR reactions for Rab11a, Rab11b and Rab25 were performed on 
extracts of A2780-DNA-3 cells and A2780-Rab25 cells. Three sets of Rab25 primer pairs were 
used; R25#1, R25#2 and R25#3 (n=3). 
B Western blots of lysates of A2780-DNA3 and A2780-Rab25 cells were incubated with anti-Rab25 
and anti-Rab11 antibodies as indicated (n=3). 
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Given that expression of Rab25 in A2780-Rab25 cells is a result of stable 
transfection of a protein expression vector, it was necessary to assess the ability 
of the antibody to detect Rab25 by Western blotting in lysates of cells which 
express endogenous Rab25.  In addition, it was necessary to establish the 
optimal concentration of antibody for routine use in Western blotting. 
Western blotting of lysates from the panel of cell lines described above with the 
anti-Rab25 antibody, confirmed that a band of the appropriate molecular weight 
was evident in those cell lines previously shown by RT-PCR to express Rab25. 
Blots were incubated with serial dilutions of the anti-Rab25 antibody to 
determine the optimal conditions for Western blotting.  Furthermore, the anti-
Rab25 antibody, used at a concentration of 0.12µg/ml (1:5000 dilution), 
produced a number of non-specific bands in addition to a band at 25kDa. When 
diluted to 0.024 µg/ml (1:10,000 dilution), only one specific small molecular 
weight band was seen 25kDa band was seen in lysates of these cells, but a 
persistent high molecular weight band of greater than 200kDa remained, the 
nature of which was not clear. It is hypothesised that this band represents non-
specific binding related to the presence of immunoglobulin within the lysate. 
However, potentially this represents non-specificity of the antibody, and further 
laboratory investigation using immunofluorescence and pre-absorbed 
immunohistochemical experiments were undertaken to assess the specificity of 
the antibody.  (Figure 3-5). 
77 
Rab25
kDa
250
50
25
10
60
1
48
4
M
CF
 1
0A
CA
1
A2
78
0R
A2
78
0C
60
1
48
4
M
CF
 1
0A
CA
1
A2
78
0R
A2
78
0C
60
1
48
4
M
CF
 1
0A
CA
1
A2
78
0R
A2
78
0C
60
1
48
4
M
CF
 1
0A
CA
1
A2
78
0R
A2
78
0C
N
o 
pr
im
ar
y 
an
tib
od
y
A
nt
i-R
ab
25
 a
nt
ib
od
y 
0.
12
µg
/m
l
A
nt
i-R
ab
25
 a
nt
ib
od
y 
0.
04
8µ
g/
m
l
A
nt
i-R
ab
25
 a
nt
ib
od
y 
0.
02
4µ
g/
m
l
 
Figure 3-5 Titration of anti-Rab25 antibody to obtain the optimum concentration for Western 
Blot detection of Rab25 in lysates from a variety of cell lines. 
Lysates from A2780-DNA3, A2780-Rab25, SNU-484, SNU-601 and MCF10a cells were subjected 
to Western blotting and the membranes incubated as indicated (n=3). 
 
 
3.2.2.3 Use of the anti-Rab25 antibody in immunofluorescence 
To validate the Rab25 antibody for use in immunofluorescence, A2780-Rab25 and 
A2780-DNA3 cells were grown on coverslips, fixed, permeabilised and incubated 
with primary and secondary antibody.  Cells were then visualised on a confocal 
microscope and images captured. 
A2780-DNA3 cells, when incubated with anti-Rab25 and anti-HA (recognising the 
epitope tag on the Rab25 expressed by these cells) antibodies, followed by the 
appropriate secondary antibody incorporating a fluorescent tag, exhibited no 
obvious signal when visualised on a confocal microscope. However, incubation of 
A2780-Rab25 cells under the same conditions revealed a clear signal with both 
the anti-Rab25 antibody and the anti-HA antibody.  The merged image of these 
two signals confirmed that the position of the anti-Rab25 signal correlated with 
the signal produced by the anti-haemagglutinin antibody (Figure 3-6). 
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3.2.3 Validation of anti-Rab25 antibody for use in 
immunohistochemistry 
3.2.3.1 Use of paraffin-embedded “pseudotissue” 
With the aim of investigating the expression of Rab25 in paraffin-embedded 
breast cancer tissue samples, it was first necessary to optimise the conditions in 
which the Rab25 antibody would be used in immunohistochemistry. Prior to using 
the antibody in archival clinical material, thrombin clots incorporating 
suspensions of A2780-DNA3 cells, A2780-Rab25 cells, SNU-484 cells and SNU-601 
cells were fixed in formalin and embedded in paraffin to create a 
“pseudotissue”. The paraffin-embedded clots were then cut on a microtome in 
2µm sections and immunohistochemistry performed.  For comparison, Rab25 and 
β-actin levels in the cells were also determined by Western blotting.  An 
immunohistochemical signal was clearly seen in those cells confirmed by 
Western blotting to express Rab25.  Minimal background signal was seen in those 
cells not expressing Rab25 (Figure 3-7).  
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Figure 3-6 The anti-Rab25 specifically recognises Rab25 in an immunofluorescence 
platform. 
A2780-Rab25 (A) and A2780-DNA3 (B) cells were fixed and incubated with antibodies recognising 
the HA epitope (green), Rab25 (red).  The primary antibodies were then visualised using 
fluorescently-conjugated secondary antibodies as indicated.  The cells were counterstained with 
DAPI (blue) to visualise the nucleus. Bar = 10um (n=3). 
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Figure 3-7 Detection of Rab25 expression by immunohistochemistry in pseudotissue 
pellets. 
A Western blots of lysates from A2780-DNA3, A2780-Rab25, SNU-484 and SNU-601 cells were 
incubated with anti-Rab25 antibody (top panel) and anti-βactin antibody (lower panel). 
B Immunohistochemical staining of A2780-DNA3, A2780-Rab25, SNU-484 and SNU-601 
pseudotissue pellets was performed (n=3). 
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3.2.3.2 Optimisation of immunohistochemical conditions 
Once it had been established that the anti-Rab25 antibody could detect Rab25 
protein in pseudotissue pellets, further investigation was required to ascertain 
the optimal experimental conditions which would produce a reliable signal with 
minimal background staining.  Serial 2µm sections from a block of a formalin-
fixed paraffin embedded breast cancer specimen were a gift from Colin Nixon. 
Immunohistochemistry was simultaneously performed under different 
experimental conditions which included no antigen retrieval, antigen retrieval 
with EDTA, Citrate and Trypsin preparations and differing concentrations of the 
anti-Rab25 antibody. 
The expected cellular distribution of Rab25 was cytoplasmic, with the potential 
for enhancement at the cellular membrane, given the observation that Rab25 is 
involved in apical recycling and co-locates with β1 integrin at the cell surface. 
(119) 
From this set of data the optimal conditions which were taken forward to 
subsequent experiments were antigen retrieval with EDTA buffer and an 
antibody concentration of 0.24µg/ml (Figure 3-8). 
To further validate the antibody for use in immunohistochemistry it was 
necessary to ensure the specificity of the staining seen. 2µm sections of formalin 
fixed, paraffin-embedded mouse bladder and sections of the breast cancer tissue 
described above were antigen-retrieved using EDTA buffer and incubated with 
secondary antibody alone, anti-Rab25 antibody at a concentration of 0.24µg/ml 
and anti-Rab25 antibody at a concentration of 0.24µg/ml that had been pre-
incubated with a 100 fold molar excess of purified GST-Rab25.  A strong signal 
was detected when the antibody was incubated under optimal conditions, whilst 
secondary antibody alone and pre-incubated antibody produce minimal 
immunohistochemical signal (Figures 3-9 and 3-10). In addition, the images in 
Figure 3-10 confirm that the anti-Rab25 antibody can produce a reliable 
immunohistochemical signal in breast cancer tissue. 
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Figure 3-8 Optimisation of conditions for immunohistochemistry. 
Sequential sections of a paraffin-embedded breast cancer specimen were prepared according to the 
indicated condition.  The antigen retrieval method is indicated vertically and the concentration of anti-
Rab25 antibody is indicated horizontally (n=3). 
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Figure 3-9 Immunohistochemical controls for anti-Rab25 antibody. 
Sections of paraffin-embedded mouse bladder incubated with no primary antibody, anti-Rab25 
antibody (2.4 µg/ml) and anti-Rab25 antibody (2.4 µg/ml) pre absorbed with an excess of purified 
GST-Rab25 protein (n=3). 
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Figure 3-10  Immunohistochemistry with anti-Rab25 antibody in breast cancer tissue. 
Sections of a paraffin-embedded breast cancer specimen incubated with no primary antibody, anti-
Rab25 antibody (2.4 µg/ml) and anti-Rab25 antibody (2.4 µg/ml) pre-absorbed with an excess of 
Rab25 protein (n=3). 
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3.2.4 The investigation of Rab25 expression in whole mouse 
tissues 
As an anti-Rab25 antibody had not previously been available, it had not hitherto 
been possible to determine the distribution of Rab25 protein expression in whole 
tissues.  Once the optimal conditions for immunohistochemistry had been 
established, immunohistochemistry using the anti-Rab25 antibody was performed 
using whole mouse tissues from multiple organs.  Human Rab25 shares 96% 
homology with mouse Rab25. In parallel with this, Western blotting of protein 
extracts of the same mouse tissues was performed to confirm the presence or 
absence of Rab25 in each tissue. Rab25 protein expression appeared to be 
localised to epithelial cells in the tissues investigated, and Western blotting of 
lysates of the same tissues with the anti-Rab25 antibody confirmed the presence 
of a 25 kDa band in those tissues which show strong staining for Rab25 by 
immunohistochemistry (Figure 3-11).  
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Figure 3-11 Use of immunohistochemistry to visualise Rab25 expression in normal mouse 
tissues. 
A Immunohistochemical staining with anti-Rab25 antibody of a mouse tissues as shown. 
B Lysates of the indicated mouse tissues were analysed by Western blotting and the membranes 
incubated with anti-Rab25 (upper panel) and anti-β-actin (lower panel) antibodies (n=2). 
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3.3 Discussion 
Prior to proceeding to investigate Rab25 expression in breast cancer tissue 
samples, it was imperative that a specific and reliable antibody was available.  
These data confirm that the affinity purification process successfully yielded a 
polyclonal rabbit antibody against Rab25 which produced reliable and 
reproducible results when used in Western blotting, immunofluorescence and 
immunohistochemistry.   Furthermore, the antibody did not recognise the very 
closely related family members, Rab11a and Rab11b.   
Affinity purification is a well validated and robust methodology for small-scale 
laboratory production of antibodies (150). Figure 3-2 clearly shows a diminution 
in signal when lysate of A2780-Rab25 cells was incubated with depleted serum, 
when compared with the same lysate incubated with crude serum, indicating 
successful extraction of the antibody from the crude serum onto the Affigel 
column.  The multiple bands present when cell lysates are incubated with crude 
serum and depleted serum are in keeping with the non-specific binding pattern 
often seen when crude serum is used in Western blotting. It was also confirmed 
that the anti-Rab25 antibody was successfully eluted from the column and when 
appropriately diluted, the anti-Rab25 antibody produced a single specific band 
of the predicted molecular weight in A2780-Rab25 cell lysate that is not present 
in A2780-DNA3 cells. 
It was noted that, when used in Western blotting, there was a marginal 
difference between the molecular weight of the band recognised by the Rab25 
antibody in the cell lines which endogenously express Rab25, when compared 
with the A2780-Rab25 stably expressing cell line (Figure 3-5.)  As previously 
detailed, the Rab25 construct used a haemagglutinin tag which may account for 
the small observed difference in molecular mass.  
For further study of Rab25 protein expression in tissues it was imperative that 
one could be confident that the affinity purified anti-Rab25 antibody did not also 
recognise the closely related family members Rab11a and Rab11b. Figure 3-3 
confirms that the anti-Rab25 antibody does not recognise a purified protein 
preparation of Rab11a.  
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The position of the signal obtained when using the anti-Rab25 antibody in 
immunofluorescence preparations of A2780-Rab25 cells can be clearly seen to be 
in the perinuclear region of the cell and no such signal is seen in A2780-DNA3 
cells (Figure 3-6.)  This is entirely consistent with previous work localising Rab25 
to this area in these cells and provides further evidence for the specificity of the 
antibody for Rab25 (119). The investigation of the anti-Rab25 antibody, as 
outlined above, yielded sufficient evidence to be confident in the specificity of 
the antibody, such that it was possible to move forward toward the ultimate 
goal of investigating Rab25 expression in breast cancer tissue samples. 
Given that well-prepared human cancer tissue with associated clinical data is a 
precious resource, it was necessary to optimise the immunohistochemistry 
technique in non-human tissue prior to proceeding to human tissue.  
Furthermore, it is well recognised that non-specific immunohistochemical 
staining can be problematic, even with well-characterised antibodies (151). For 
these reasons the immunohistochemistry technique was first applied to 
“pseudotissues” of A2780-Rab25, A2780-DNA3 SNU-484 and SNU-601 cells.  Figure 
3-7 illustrates that that when these sections were incubated with the anti-Rab25 
antibody, a strong immunohistochemical stain was achieved in those cell types 
known to express Rab25. Some background staining is seen in the control cells, 
and taking into account the additional high molecular weight bands seen in 
Western blotting in Figure 3-5, this raises the possibility of non-specificity of the 
antibody. However, the specificity of the staining seen in the 
immunofluorescence images in Figure 3-6, and the significant reduction in 
immunohistochemical staining with pre-absorption of the antibody seen in 
figures 3-9 ands 3-10, suggests that the antibody is producing real staining. 
These important observations added further supporting evidence that the anti-
Rab25 antibody would be sufficiently sensitive and specific to yield reliable 
results in the investigation of Rab25 expression in human breast cancer. 
To further maximise the staining obtained by immunohistochemistry, it was 
necessary to optimise the experimental conditions.  The fixation of fresh tissue 
in formalin causes significant chemical changes in the antigens of the tissue 
which leads to masking of the antigen from the antibody with which the tissue is 
incubated (152).  The mechanisms by which this happens are essentially 
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unknown, but the changes have been shown to be reversible with high 
temperature heating (153).  Manipulation of the composition of the solution in 
which the slides are heated can further enhance the extent to which antigens 
are retrieved.   However, no single set of conditions has been shown to be 
optimal for all antibodies and, as such, it has become standard practice to 
determine the optimal conditions for a particular antibody using the “test 
battery” method. The antigen retrieval solutions used in the test battery for the 
anti-Rab25 antibody included citrate, EDTA and trypsin buffers and the results 
were compared with antigen retrieval with distilled water alone.  In addition to 
the optimisation of the antigen retrieval method, it was necessary to ascertain 
the optimal concentration of anti-Rab25 antibody, which would provide a strong 
positive signal with minimal background staining.  Figure 3-8 demonstrates the 
results obtained from the anti-Rab25 antibody “test battery,” which 
incorporated both the method of antigen retrieval and concentration of 
antibody. From this experiment it can be seen that the optimal conditions for 
immunohistochemistry with the anti-Rab25 antibody were antigen retrieval with 
EDTA buffer and an antibody concentration of 2.4µg/ml and these parameters 
were adopted as the standard conditions for subsequent experiments. 
Previous studies had indicated that Rab25 mRNA expression was most prevalent 
in the kidney, lung and mucosal layer of the stomach of rabbit and absent in 
other tissues such as brain, skeletal muscle and liver, leading these authors to 
hypothesise that Rab25 expression was limited to specific epithelial cells (99). 
More recent work, using steady state mRNA expression profiling and 
computational hierarchical clustering methods, has provided datasets which 
allow the expression profile of all Rab proteins in 79 human and 61 mouse tissues 
to be investigated (154).  The expression profiles of individual rab proteins was 
generated using from the Human and Mouse Gene Atlases, which are publicly 
available datasets on normal human and mouse tissues. This “Membrome” 
dataset confirms that Rab25 mRNA expression is most prevalent in organs which 
have high proportion of epithelial tissue in relation to total organ mass, for 
example lung, tongue and skin.  However, as the membrome has been developed 
from whole tissue samples, those tissues which have an epithelial component 
which is a much smaller component of the total organ mass, for example kidney 
and pancreas, show relatively lower Rab25 mRNA expression.   
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The data presented thus far confirm that the polyclonal anti-Rab25 antibody can 
reliably detect Rab25 in whole tissue samples.  To confirm the findings of 
Goldenring (99) - that Rab25 protein expression was confined to epithelial cells -  
immunohistochemistry was performed on sections of whole mouse tissue, whilst 
Western blotting the same tissues concurrently. Figure 3-11 demonstrates clearly 
that Rab25 expression is present in the epithelial cell layer of small and large 
intestine, lung, kidney and pancreas of mouse tissue.   
Of some interest is the observation that lysates from splenic tissue, when 
subjected to Western blotting, produced a band of predicted molecular weight 
when incubated with anti-Rab25 antibody, despite the spleen containing minimal 
epithelial elements. However, immunohistochemistry of the same tissue with 
anti-Rab25 antibody produced minimal signal. One explanation for this 
discrepancy is that dissection of the spleen can be technically difficult, 
particularly when performed by an inexperienced operator, and it is feasible 
that at the time of dissection the splenic tissue sample was contaminated with 
other intra-abdominal tissue, particularly small intestine or colon, both of which 
have now been shown to be high expressors of Rab25.  However, the spleen was 
the only tissue of the lymphoreticular system to be investigated, and it is 
possible that elements of this system may express Rab25, but further 
investigation of this possibility was beyond the scope of this research.  
In summary, the data presented here confirm that the affinity purification of a 
polyclonal anti-Rab25 antibody from rabbit serum was successful. Furthermore, 
the resulting antibody has been shown to produce reliable and consistent results 
when used in Western blotting, immunofluorescence and immunohistochemistry. 
For the first time it has been confirmed that Rab25 protein expression is 
confined to epithelial tissues and appears to be ubiquitous across a number of 
different, highly specialised epithelia. 
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4 Investigation of Rab25 protein expression in 
breast cancer. 
4.1 Introduction 
4.1.1 Laboratory identification of predictive markers in breast 
cancer 
As discussed in Chapter 1, the importance of hormone receptor status in 
predicting response to treatment in breast cancer has been known for decades.  
Historically the assessment of hormone receptor expression in breast cancer 
specimens was by biochemical methods, the most widely used being the dextran 
- coated charcoal method which gave a quantitative measure described as 
fmol/mg of cytosolic protein. This method required fresh tissue and could be 
influenced by a number of factors including contamination by normal breast 
tissue and exposure to exogenous oestrogens such as the oral contraceptive pill.  
Immunohistochemistry has been shown to be superior to biological methods of 
hormone receptor detection, having a greater sensitivity and specificity (155). 
However, as discussed in section 1.4.1, a high standard of quality assurance is 
required to produce consistently correct results. Despite the limitations and 
potential for variability of reporting which is inherent in immunohistochemistry, 
it is now the main technique used in identifying prognostic and predictive 
markers in clinical diagnostic laboratories and automated systems are well 
established.  
While newer molecular techniques such as real time RT-PCR are in routine use in 
research laboratories, the resource implications and lack of automated systems 
means that at the present time such techniques are not feasible in clinical 
practice. In addition, any new test would have to be shown to be significantly 
superior to current techniques.  As a result, for novel markers identified in a 
research setting which may have prognostic or predictive importance to be 
utilised in clinical practice, the techniques to identify them must be compatible 
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with current processes. In the main, this means the ability to detect the novel 
marker of interest with immunohistochemistry. 
4.1.2 Immunohistochemical scoring systems in breast cancer 
As previously described, there are many factors which can affect the eventual 
immunohistochemical result. Arguably the most important factor is that the 
assessment of the extent and intensity of the staining is subjective, and 
therefore the potential for error is moderate. In an attempt to standardise how 
immunohistochemical staining of breast cancer is reported, a number of scoring 
systems have been devised. The histo-score involves assessing the percentage of 
cells which stain on a 4 –point score of intensity, where 0 = no staining, 1 = 
weak, 2 = moderate and 3 = strong staining. The summation of each intensity 
score then produces the histo-score in the range 0-300 (156).  The Quick score 
involves a score from 1-3 for intensity and a score from 1-4 based on the 
proportion of cells stained, which is then added together to give a maximal score 
of 7 (15).  The Allred score is a modified version of the Quick score and expands 
the lower end of proportion of staining to give a score of 1-5 and an overall 
maximal score of 8 (157). Other systems give a percentage of cells stained 
regardless of intensity of staining.  
In breast cancer diagnosis, an individual pathological specimen is routinely 
stained for ER, PR and HER2. ER staining is nuclear and different institutions use 
a variety of the scoring systems outlined. Assessment of HER2 status tends to be 
more uniform using the HerceptTest, which gives a score of 0, 1+, 2+ or 3+ 
depending on the intensity of the membrane staining. Borderline 2+/3+ cases 
may be further assessed using fluorescent in-situ hybridisation to confirm the 
HER2 status (158). 
The recognition that scoring systems are central to robust and reproducible 
immunohistochemical assessment led the European Organisation for Research 
and Treatment of Cancer (EORTC) to issue a consensus statement on 
immunohistochemical scoring (159). This gave guidance on developing scoring 
systems for new and existing immunohistochemical tests which includes defining 
the relevant pattern of staining, defining a “cut-off” value for each category of 
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staining intensity and selecting areas to be assessed and reiterated the needs for 
robust quality assurance systems. 
4.1.3 Tumour tissue microarrays 
The high throughput immunohistochemistry technology described above has 
been made possible by the introduction of tissue microarray (TMA) technology.  
A TMA is created by embedding small cores of individual pathological specimens 
into a recipient paraffin block which can contain up to 1000 specimens. 
Simultaneous histological analysis can then be carried out on a large number of 
patient samples (160). This allows all samples included within the TMA to be 
subjected to identical processing techniques, reducing significantly the 
variability in staining conditions (161).  A criticism of this methodology is that 
only a small section of the tumour is examined and this may be of importance in 
cases where antigen expression may not be homogeneous across the whole 
tumour. Despite this potential drawback, microarray technology is widely used in 
clinical and research laboratories to assess the expression of the protein of 
interest in a large cohort of patients.  
4.1.4 Observer variability in immunohistochemical scoring 
It is widely accepted that because of the subjective nature of 
immunohistochemical reporting, significant inter-observer variation may occur 
and published research papers invariably quote a measure of inter-observer 
variation. Historically, the most commonly quoted measure of variability is the 
kappa score, which corrects the proportion of agreement due to chance. The 
strength of agreement is measured on scale from 0-1,correlation being  
described as 0 – 0.2 = slight , 0.21 – 0.4  = fair , 0.41 – 0.6 moderate , 0.61 – 0.8 
substantial and 0.81-1 almost perfect (162). 
More recently, the interclass correlation coefficient has been shown to be a 
consistent method to calculate inter-observer variability in 
immunohistochemistry, when the scoring being analysed generates continuous, 
rather than discrete, data. The strength of agreement is measured as 0.7 = 
minimal acceptable standard, 0.8 = good and >/= 0.9 as excellent (163). 
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4.1.5 Investigation of Rab25 expression in breast cancer 
As described in 1.6.2, there are significant discrepancies between the published 
data with regard to the patterns of expression of Rab25 in breast cancer.  The 
studies published thus far have studied Rab25 expression at the RNA level using 
RT-PCR. Studies at the mRNA level are based on the assumption that mRNA 
levels are predictive of expressed protein levels, however only limited studies 
have been undertaken to explore this hypothesis. In general whilst an overall 
correlation between mRNA levels and protein levels has been shown, the 
strength of the correlation varies markedly between genes and between 
individuals (164).  There is therefore merit in investigating the protein 
expression patterns of Rab25 and the relationship between Rab25 expression and 
clinical outcome in breast cancer in an attempt to further the understanding of 
the effect of this protein in this disease and to ascertain if Rab25 expression is a 
useful prognostic or predictive marker in breast cancer.  
4.1.5.1 Development of a scoring system for immunohistochemical staining 
of breast cancer tissue with anti-Rab25 antibody 
Given that the anti-Rab25 antibody had not previously been used for 
immunohistochemical applications, it was necessary to develop a scoring system 
to quantify the intensity of immunohistochemical signal produced.  Prior to 
investigation of Rab25 expression in breast tissue, the properties of the antibody 
were characterised as described in Chapter 3. The development of the scoring 
system was made with reference to the EORTC consensus statement described 
above. 
4.1.5.2 Investigation of Rab25 protein expression in archival clinical breast 
cancer tissue 
To determine if there is a relationship between Rab25 protein expression and 
clinical outcome in breast cancer, immunohistochemistry was performed on a 
large cohort of breast cancer samples to give meaningful, statistically robust 
results.  
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Cores from breast cancer tissue from 566 primary breast cancers samples from 
patients who had been treated at Glasgow Royal Infirmary between 1984 and 
1998 had previously been compiled in a tissue microarray – the West of Scotland 
breast cancer cohort.  Pathological and clinical outcome data were available for 
all patients.  
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4.2 Results 
4.2.1 Intensity of Rab25 immunohistochemical staining can be 
categorised by a simple numeric grading system 
Using the commercially available BR804 breast tissue microarray which contains 
35 cores of breast cancer tissue, each with a paired adjacent normal breast 
tissue core, immunohistochemistry was performed using the anti-Rab25 
antibody.   Figure 4-1 shows images which represent grade 1 = weak, grade 2 = 
moderate and grade 3 = strong staining of breast cancer samples. The 
percentage of cells stained in each core is approximately 100% and the intensity 
of staining was relatively homogeneous across each core. There were no cores in 
which staining was absent. This was performed by two independent observers, 
Dr Brendan Doyle and me, blinded to the available clinical data and was 
performed on two separate TMA slides. Positive and negative control slides of 
A2780-Rab25 and A2780-DNA3 tissue pellets were stained alongside each 
experiment.  
A CB
 
Figure 4-1 Immunohistochemical staining of breast cancer specimens with anti-Rab25 
antibody. 
Images demonstrate A Grade 1 weak staining, B Grade 2 moderate staining and C Grade 3 strong 
staining from a commercial TMA containing cores of breast cancer. All samples were processed 
simultaneously. Representative images shown. 
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It was observed that when staining was present, it was confined to the epithelial 
elements within the specimen and that stromal cells did not stain. 
Corresponding hematoxylin and eosin staining was performed on a sequential 
section for comparison. Staining was present at the same intensity across the 
whole specimen and the proportion of the sample stained approached 100% . It 
was therefore deemed impractical to develop a histoscore system based on both 
intensity and frequency of staining. 
Figure 4-2 shows the frequency of each grade of staining of the non-malignant 
adjacent breast tissue (which is described as “normal” breast tissue by the 
manufacturer,) and breast cancer samples present on the BR804 tissue 
microarray slide and Table 4-1 shows the results of the Kolmogorov-Smirnov test 
of normality for these data which confirms that the expression of Rab25 
observed in these samples is normally distributed. 
To validate this scoring system further the process was repeated on a second 
commercial tissue microarray, BR1001, containing 40 cores of primary breast 
cancer tissue with paired samples of metastatic lymph node deposits from the 
same patient.  Figure 4-3 shows the frequency of each grade of staining of the 
primary breast cancer and matched metastatic samples present on the BR1001 
TMA. Table 4-2 shows the results of the Kolomogorov-Smirnov test for normality 
which confirms that the data in this case are not normally distributed. Despite 
the observation that the data are not normally distributed, there is still an even 
distribution of samples across the grading categories. 
4.2.2 Level of Rab25 expression in normal breast tissue does not 
correlate with Rab25 expression level in matched cancer 
tissue 
Statistical analysis of the BR804 dataset was carried out to ascertain if there was 
a correlation between Rab25 expression in normal breast cancer tissue and 
paired cancer tissue.  Power calculations to determine sample size required to 
detect a correlation were performed using GPower 3.1 software.  The number of 
paired cases to achieve a 95% power with a significance level of 0.005 is 13. The 
BR804 TMA contained 35 pairs of matched samples and the sample size was 
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therefore adequately powered to detect a significant difference if one was 
present. 
As described above and shown in Table 4-1, the expression of Rab25 in the cores 
present on the BR804 TMA was normally distributed in both “normal” breast 
tissue and matched breast cancer tissue.  However, there was no direct 
relationship between the expression level observed in “normal” tissue and the 
matched cancer sample.  Table 4-3 shows the crosstabulation of Rab25 score 
between “normal” breast tissue and matched primary cancer tissue and also the 
number of pairs in which the “normal” tissue had a higher Rab25 score than the 
paired cancer, the number of pairs in which the “normal” tissue had a lower 
Rab25 score than the paired cancer and the number of pairs where the Rab25 
score was identical in both “normal” tissue and cancer.  To quantify the 
relationship between the Rab25 expression in “normal” and breast cancer tissue 
Pearson’s coefficient was calculated as r = 0.293 ( two tailed p-value 0.088) 
giving an r2 = 0.086, confirming that there is no significant correlation between 
Rab25 expression levels in the “normal” breast tissue and paired cancer tissue in 
this dataset. 
4.2.3 Level of Rab25 expression in primary breast cancer tissue 
does not correlate with Rab25 expression level in matched 
metastatic breast cancer tissue 
Statistical analysis of the BR1001 dataset was carried out to investigate if there 
was a correlation between the Rab25 expression level in primary breast cancer 
and the level seen in matched locoregional lymph node deposits.  The BR1001 
TMA contained 40 pairs of matched samples and the sample size was therefore 
adequately powered to detect a significant difference if one was present. 
Table 4-4 shows the crosstabulation of Rab25 score between primary breast 
cancer and matched metastatic cancer tissue and also the number of pairs in 
which the primary cancer tissue had a higher Rab25 score than the paired 
metastasis, the number of pairs in which the primary cancer tissue had a lower 
Rab25 score than the paired metastasis and the number of pairs where the 
Rab25 score was identical in both primary cancer tissue and metastasis.  As the 
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data were not normally distributed the relationship between the Rab25 
expression in primary cancer tissue and paired metastatic tissue was assessed 
using the non-parametric Wilcoxon Signed Ranks test, p = 0.400. Given that the 
sample size was adequately powered, this confirms that there is no correlation 
between the Rab25 expression level in primary breast cancer and paired 
metastatic deposits in this dataset. 
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Figure 4-2 Distribution of the immunohistochemical intensity scores in the BR804 tissue 
microarray. 
Frequency of Rab25 immunohistochemical staining characterised as Grade 1 (weak), Grade 2 
(moderate) or Grade 3 (strong) in the BR804 tissue microarray in A normal breast tissue and B 
matched cancer tissue. Representative data shown (n=2) as both immunohistochemical runs 
produced identical results. 
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Table 4-1 Test of normality for Rab25 staining intensity results obtained from the BR804 
breast cancer tissue microarray. 
.215 .082 yes
.223 .077 yes
Rab25 Score Normal
Rab25 Score Cancer
Statistic p value
passed
normality
test?
Kolmogorov-Smirnov
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Figure 4-3 Distribution of the immunohistochemical intensity scores in the BR1001 tissue 
microarray. 
Frequency of Rab25 immunohistochemical staining characterised as Grade 1 (weak), Grade 2 
(moderate) or Grade 3 (strong) in the BR1001 tissue microarray in A primary breast cancer tissue 
and B matched metastatic lymph node deposits. Representative data shown (n=2) as both 
immunohistochemical runs produced identical results. 
101 
 
Table 4-2 Test of normality for Rab25 staining intensity results obtained from the BR1001 
breast cancer tissue microarray. 
.255 0.0097 no
.243 0.0058 no
Rab25 Score Primary
Rab25 Score Metastasis
Statistic p value
passed
normality
test?
Kolmogorov-Smirnov
 
Table 4-3 Cross tabulation of Rab25 score in matched normal and cancer tissue on the 
BR804 tissue microarray. 
The number of pairs in which the score in normal tissue compared with primary cancer tissue is 
higher, lower and identical is shown. Count
6 5 1 12
2 3 8 13
1 7 2 10
9 15 11 35
1.00
2.00
3.00
Cancer tissue
Rab25 score
Total
1.00 2.00 3.00
Normal tissue Rab25 score
Total
Rab25 Score
Normal < Cancer
Normal > Cancer
Ties
10
14
11
Pairs
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Table 4-4 Cross tabulation of Rab25 score in matched primary breast cancer and matched 
metastatic lymph node tissue on the BR1001 tissue microarray. 
The number of pairs in which the score in metastatic tissue compared with primary cancer tissue is 
higher, lower and identical is shown. 
 
Rab25 Score
Metastasis < Primary
Metastasis > Primary
Ties
16
10
15
Pairs
6 5 1 12
2 3 8 13
1 7 2 10
9 15 11 35
1.00
2.00
3.00
Cancer tissue
Rab25 score
Total
1.00 2.00 3.00
Normal tissue Rab25 score
Total
Primary Cancer
Metastasis 
Rab25 score
6
5
3
14 15 12
8
5
2
3
5
4
17
15
9
41
 
4.2.4 Rab25 expression in a large clinical cohort 
Sections from the West of Scotland breast cancer tissue microarray, and access 
to the clinical database, were gifts from Dr Joanne Edwards and were 
constructed as described in Section 2.1.5.2. Ideally TMA’s should incorporate 
two or more cores from each sample, however, due to the large number of cases 
required to produce statistically robust results in studies involving breast cancer, 
a single core for each cancer was selected. 6 TMA’s in total were constructed. 
Corresponding clinical data were available and included age at diagnosis, tumour 
type, grade, size, nodal status, overall survival in days, oestrogen and HER2 
receptor status. ER status was determined from the original pathological 
assessment at the time of surgery, and the Her2 status was determined using 
standard diagnostic immunohistochemical techniques on the constructed TMA. 
This was performed by Claire Orange, Department of Pathology, Glasgow 
University. A tumour was deemed to be ER positive if greater than 10% of cell 
stained positive for oestrogen receptor and HER2 positive if Hercept Test scoring 
was 3+. Details of post-operative treatment were not available. Table 4-5 gives 
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details of the baseline histopathological characteristics of the tumour samples 
included on the TMA. 
Immunohistochemistry was performed on the TMA sections and slides were 
scored independently by two individuals, me and Dr Brendan Doyle, Specialist 
Registrar in Histopathology, using the grade 0-3 scoring system devised from the 
observations from the commercial TMAs.  Inter-observer variability was assessed 
by calculation of Kappa score of 0.69.  Those cores in which the observers 
disagreed were reassessed by both observers together and a consensus reached. 
Statistical analysis, including Kaplan-Meier life table analysis and Cox regression 
was performed using SPSS version 15 software. The terminal event used to assess 
survival was breast cancer related death.  
In this breast cancer clinical cohort, 35.5% of tumours stained weakly, 46.7% 
stained moderately and 17.8% stained strongly for Rab25. Kaplan Meier survival 
curves were plotted for each of the levels of expression and test of equality of 
survival distributions of the different levels of Rab25 cytoplasmic scores was 
performed (Log Rank test.)  
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Table 4-5 Baseline characteristics of the tumour samples on the West of Scotland Breast 
Cancer tissue microarray. 
Variable Number of cases 
Histopathological type  
Ductal 491 
Lobular 29 
Other 13 
Missing 28 
Histopathological Grade  
I 50 
II 258 
III 235 
Missing 18 
Size  
<20mm 178 
20-49mm 231 
>50mm 35 
Missing 117 
Oestrogen Receptor Status  
Negative 137 
Positive 329 
Missing 95 
Nodal Status  
Negative 254 
Positive 247 
Missing 60 
Her2 status  
Negative 451 
Positive 48 
Missing 62 
Rab25 Score  
Grade 1 199 
Grade 2 262 
Grade 3 100 
    
 
Univariate analyses and relative distribution of Rab25 cases relative to standard 
clinicopathological features are demonstrated in Table 4-6. 
105 
Table 4-6 Univariate analyses of Rab25 score in relation to known clinicopathological 
features in the West of Scotland Breast Cancer Cohort 
 Rab25 Score Χ2 p-value 
 1 2 3 
Age  
 
<50 45 73 26 0.387 
>50 148 182 72 
Histopathological Grade  
 
1 24 23 3 0.40 
2 81 121 56 
3 87 110 97 
Size  
 
<20 mm 64 88 26 0.772 
21-49 mm 79 108 44 
>50 mm 14 15 6 
Lymph node status  
 
Positive 78 130 46 0.194 
Negative 94 109 44 
Oestrogen Receptor 
Status 
 
 
Positive 118 152 59 0.447 
Negative 52 67 18 
HER2 Status  
 
Positive 166 212 73 0.612 
Negative 16 26   
 
 
The Kaplan-Meier survival curves for the total cohort is shown in Figure 4-4A and 
demonstrates that while the Kaplan Meier curves for survival cross, giving the log 
rank test low power to detect a true difference in breast cancer related survival 
between the three groups, there is a trend towards decreased survival with 
Grade 1 Rab25 staining, compared with Grade 2 and 3 staining.  Further analysis 
confirmed no significant difference (p = 0.679, log rank test and hazard ratio 
0.895, 95% CI 0.53-1.52) in the cumulative survival of patients whose tumours 
were scored as either moderate or strongly staining as shown in Figure 4-4B, and 
the data from these two groups were combined as “Rab25 positive” tumours, as 
distinct from the weakly staining “Rab25 negative” tumours, for further analysis.  
The Kaplan-Meier survival curves comparing the survival outcomes of patients 
with Rab25 positive tumours with those of patients with Rab25 negative tumours 
is shown in Figure 4-4C. Patients with Rab25 negative tumours showed a 
significantly reduced breast cancer specific survival when compared with 
patients with Rab25 positive tumours (p = 0.001, log rank test and hazard ratio 
0.577, 95% CI 0.41-0.81.)  
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As the Kaplan Meier survival curves illustrated in Figure 4-4 converge or cross, 
the values given for log rank test and hazard ratio should be interpreted with 
caution. They are included here to illustrate the trends observed only as there is 
a clear departure from proportional hazard with increasing time. 
4.2.5 Loss of Rab25 expression has a greater negative effect on 
survival of patients who have ER negative tumours 
compared with patients who have ER positive tumours 
Of the 566 samples analysed, oestrogen receptor status was available for 466 
cases; 329 were oestrogen receptor positive and 137 were oestrogen receptor 
negative. Subgroup analysis of the effect of Rab25 expression on the breast 
cancer related survival of those patients whose tumours have lost ER expression 
is shown in Figure 4-5B. These data demonstrate that patients with ER negative, 
Rab25 negative tumours had significantly reduced survival when compared with 
patients with ER negative Rab25 positive tumours, p = 0.015, log rank test, 
hazard ratio 0.51 (95% CI 0.30-0.87.)  In patients who had tumours which had 
lost Rab25 expression, mean breast cancer related survival was 9.9 years (95% CI 
7.5 – 12.3 years) compared with 13.3 years (95% CI 11.5 – 15.1 years) in patients 
with tumours which expressed Rab25. This represents an absolute reduction in 
10 year survival of 3.4 years, which is approximately 22%, for those patients with 
an ER negative, Rab25 negative tumour, compared with those patients with an 
ER negative, Rab25 positive tumour. 
The Kaplan-Meier curves illustrating the survival of patients with Rab25 negative 
or Rab25 positive tumours in patients whose tumours express the ER receptor are 
shown in Figure 4-5A.  In this subgroup the effect of Rab25 loss is much less than 
in the ER negative cohort, p = 0.03, log rank test, hazard ratio 0.59 (95% CI 0.36-
0.97) with mean breast cancer related survival in patients with weak Rab25 
staining of 13.8 years (95% CI 11.9 - 15.8 years) compared with 15.1 years (95% 
CI 13.7-16.5 years) in patient with moderate or strong staining. However, as 
described previously, these curves cross at 10 years, suggesting that there is 
unlikely to be a statistically significant difference between these two groups. 
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These data reveal that loss of Rab25 has a significantly greater effect on the 
survival of patients who have tumours which have also lost expression of the 
oestrogen receptor. 
4.2.6 Loss of Rab25 has maximal negative effect on the survival 
of patients with ER negative tumours that do not 
overexpress the HER2 receptor  
Further analysis of the 137 patients with ER negative tumours revealed that the 
survival in those patients who had lost expression of Rab25 was further reduced 
in those patients whose tumours were deemed to be Her2 negative (score = 0,1+ 
or 2+) using the Hercept Test for HER2 expression. Of the 137 patients with ER 
negative tumours, 107 were also HER2 negative and 23 were Her 2 positive, 
described as 3+ using the Hercept Test.   
Figure 4-6A demonstrates the breast cancer related survival of those patients 
whose tumours have lost ER expression and do not overexpress the HER2 
receptor, as determined by immunohistochemical analysis. These data 
demonstrate that patients with ER negative, HER2 negative and Rab25 negative 
tumours had significantly reduced survival when compared with patients with 
Rab25 positive tumours, p = 0.005, log rank test, hazard ratio 0.43 (95% CI 0.23-
0.79.)  In patients with weak Rab25 staining, mean breast cancer related survival 
was 9.6 years (95% CI 7.0 – 12.2 years) compared with 13.8 years (95% CI 10.5 – 
15.8 years) in patients with moderate or strong staining.   
For comparison, the estimated survival plot showing the survival of patient with 
ER positive/HER2 negative cancer is shown in Figure 4-6B. In this subgroup the 
effect of Rab25 loss is much less than in the ER negative/HER2 negative cohort, 
p = 0.013, log rank test, hazard ratio 0.89 (95% CI 0.67-1.04). However, as 
described previously, these curves cross at 10 years, suggesting that there is 
unlikely to be a statistically significant difference between these two groups. 
Estimated survival plots showing the effect of Rab25 status on patients with ER 
negative Her2 positive breast and ER positive Her2 positive cancer are not shown 
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as the number of patients with these tumour profiles was too small to yield 
meaningful results.  
This represents an absolute reduction in 10 year survival of 4.2 years, which is 
approximately 26%, for those patients with an ER negative, Her2 negative Rab25 
negative tumour, compared with those patients with an ER negative, Her2 
negative Rab25 positive tumour. 
4.2.7 Loss of Rab25 is an independent prognostic indicator in 
breast cancer survival  
In order to fully assess the effect of Rab25 on breast cancer related survival, 
Cox’s multiple regression analysis was performed to control for the confounding 
variables of tumour size and grade, extent of lymph node involvement at the 
time of diagnosis and ER status. The Cox model provides an estimate of the 
effect of Rab25 loss after adjustment for the other known prognostic variables 
and gives an indication as to whether the effect of Rab25 loss is independent of 
these variables. 
Table 4-7(A) shows the results of the Cox’s multiple regression analysis to 
investigate the relationship between the prognostic factors described above.  
The data show that the hazard ratio for death in the Rab25 positive group is 0.59 
of that of the Rab25 negative group, which represents a 40% decrease in the risk 
of death in the Rab25 positive group after adjustment for the other factors in 
the model. The significance of this result is demonstrated by the p value of 
0.019. 
Table 4-7(B) shows the manner in which categorical variables were handled in 
the model, which is necessary to interpret the individual regression coefficients 
given. 
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A
Years
B
Years
C
Years
p = 0.005
HR Grade 2 = 0.59 CI 0.42-0.86
HR Grade 3 = 0.53 CI 0.32-0.89
p = 0.679
HR  = 0.895 CI 0.53-1.52
p = 0.001
HR  = 0.58 CI 0.41-0.81
2 4 6 8 10
2 4 6 8 10
2 4 6 8 10
 
Figure 4-4  Kaplan Meier curves to estimate the overall breast cancer related survival of 
patients with low, medium or high expression of Rab25 in a cohort of 566 breast cancer 
cases. Legend continues on next page 
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Figure 4-4 Kaplan Meier curves to estimate the overall breast cancer related survival of 
patients with low, medium or high expression of Rab25 in a cohort of 566 breast cancer 
cases. Log rank test has been performed  to compare survival between each group and hazard 
ratios are given. However, these  results should be interpreted with caution as in this situation the 
log rank test has low power to detect a true difference and a statistically significant difference is 
unlikely to exist. Grade 1 is the reference indicator. 95% confidence intervals are shown. 
Grade 1 – indicated in blue 
Grade 2 – indicated in green 
Grade 3 – indicated in red 
Grade 2&3 combined - indicated in yellow 
(A) Total cohort all grades 
(B) Total cohort grade 2 and grade 3  
(C) Total cohort grade 1 and grades 2&3 combined 
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Years
A
p = 0.03
HR 0.59 CI – 0.36-0.97
B
Years
p = 0.01
HR 0.51 CI – 0.30-0.87
2 4 6 8 10
2 4 6 8 10
 
Figure 4-5 Kaplan Meier survival curves to estimate the overall survival of patients who have 
breast tumours which express, or have lost expression, of Rab25. 
Log rank test was performed to compare survival between Rab25 positive and negative tumours 
(p-values shown.) Hazard ratio for death is also shown.  Grade 1 is the reference indicator. Hazard 
ratio values should be interpreted with caution when survival curves cross as a statistically 
significant difference is unlikely to exist in this situation. 
Grade 1 – indicated in blue 
Grade 2&3 combined – indicated in yellow 
(A) Oestrogen receptor positive tumours (n=329) 
(B) Oestrogen receptor negative tumours (n=137) 
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Years
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Years
p = 0.005
HR 0.43 CI 0.23-0.79
p = 0.013
HR 0.89 CI 0.67-1.04
A
B
 
Figure 4-6 Kaplan Meier curves to estimate overall survival of patients who have breast 
tumours which express or have lost Rab25 expression in the ER-/Her2- and ER+/Her2- 
cohorts 
(A) ER negative/Her2 negative tumours 
(B) ER positive/Her2 negative tumours 
Log rank test was performed to compare survival between Rab25 positive and negative tumours (p 
values shown.) Hazard ratio for death is also shown. Grade 1 is the reference indicator. 
Grade 1 – indicated in blue 
Grade 2&3 combined – indicated in yellow 
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Table 4-7 Cox’s multiple regression model to assess the impact of breast cancer size, grade, 
nodal status, oestrogen receptor status, HER2 status and Rab25 status on survival. 
A B – estimated coefficient, SE – standard error, Wald – ratio of B to SE squared, Sig – 
significance of Wald statistic, Exp(B) – Hazard ratio. B Categorical variables coding to demonstrate 
how categorical variables were treated during the analysis. 
Categorical Variable Codingsc,d,e,f,g,h
24 1 0
160 0 1
170 0 0
141 1 0
188 0 1
25 0 0
180 1
174 0
114 1
240 0
319 1
35 0
125 1
229 0
1
2
3
gradeb
1.00
2.00
3.00
sizecodeb
1.00
2.00
Nodestatus b
0
1
ercodeb
0
1
HER2bi3b
1.00
2.00
Rab252and3combb
Frequency (1)a (2)
The (0,1) variable has been recoded, so its coefficients will
not be the same as for indicator (0,1) coding.
a. 
Indicator Parameter Codingb. 
Category variable: gradec. 
Category variable: sizecode (<20=1, 20-49 =2, >50=3)d. 
Category variable: Nodestatus (1=neg, 2=pos)e. 
Category variable: ercode (ER>10 is classed as positive =1,
negative =0)
f. 
Category variable: HER2bi3 (HER2 3+pos)g. 
Category variable: Rab252and3comb (Rab252and3comb)h. 
Variables in the Equation
42.505 2 .000
-2.035 .358 32.238 1 .000 .131
-1.782 .297 35.959 1 .000 .168
4.095 2 .129
-1.370 1.034 1.756 1 .185 .254
-.463 .273 2.890 1 .089 .629
-.807 .255 10.025 1 .002 .446
.885 .256 11.946 1 .001 2.423
.040 .336 .014 1 .906 1.041
.594 .232 6.553 1 .010 1.812
sizecode
sizecode(1)
sizecode(2)
grade
grade(1)
grade(2)
Nodestatus
ercode
HER2bi3
Rab252and3comb
B SE Wald df Sig. Exp(B)
Cox’s Multiple Regression model fitted to data from the 
West of Scotland Breast Cancer Cohort 
Categorical Variable Codings
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4.3 Discussion 
The data reported here demonstrate for the first time that 
immunohistochemistry with an anti-Rab25 antibody produces staining patterns 
which can be graded by a semi-quantitative scoring system, and that application 
of this scoring system can produce clinically significant observations with regard 
to Rab25 expression in a large breast cancer population.  
As there was no previous work using an anti-Rab25 antibody for 
immunohistochemistry, it was first necessary to ascertain if there was a 
spectrum of intensity of staining  which would be amenable to a semi-
quantitative scoring system.  It was not possible to predict in advance if there 
would be any difference in the intensity of staining produced, particularly as 
immunohistochemistry using diaminobenzidine (DAB) is only stoichiometric at 
low levels of intensity (165), thus if the spectrum of Rab25 in breast tissue was 
beyond the stoichiometric threshold of DAB, it might not have been possible to 
visually detect any difference between samples.   Similarly, it was possible that 
there would not be a detectable difference in Rab25 expression between breast 
cancer samples, and it was necessary to produce robust evidence to support the 
hypothesis that Rab25 protein expression levels did vary between samples, and 
that this variation could be quantified in a reproducible manner, before 
proceeding to further investigation using the clinical TMA. 
Results obtained from the BR804 and BR1001 commercial TMA’s confirmed that 
Rab25 expression could indeed be graded using a semi-quantitative scoring 
system comprising of Grade 1(weak), Grade 2 (moderate) or Grade 3 (strong) 
staining.  The observation that individual cores stained with the same intensity 
across the whole core confirmed that a semi-quantitative scoring system which 
did not include the percentage of cells stained was sufficient to accurately 
represent the staining patters seen. Inter-observer variation was calculated to 
be within the acceptable range.  
In addition, the distribution of this staining was spread across the three grades, 
suggesting that Rab25 protein levels did vary sufficiently between individual 
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breast cancer samples to allow the data generated from a large clinical cohort 
to be interrogated using standard statistical tests.  
Investigation of the relationship between Rab25 protein expression in normal 
breast tissue and matched primary breast cancer, using the BR804 commercial 
TMA, was in response to the findings of Cheng et al. as outlined in section 1.6.2 
(107). In the work presented here, demonstrable variation in Rab25 protein 
expression can be seen in normal breast tissue and in breast cancer tissue, but 
there is no obvious direct relationship between the level of Rab25 expression in 
the normal tissue and that observed in the matched cancer sample.  In 14 out of 
35 cases (40%) the cancer sample had less Rab25 expression than the matched 
primary, which is in keeping with the findings of Cheng, which demonstrated loss 
of Rab25 mRNA by RT-PCR in 44% of breast cancer samples when compared with 
matched normal tissue (111).  
Investigation of the Rab25 expression in breast cancer and matched metastatic 
lymph nodes in the BR1001 commercial TMA demonstrated that there is no direct 
relationship between the Rab25 expression level in primary breast cancer and 
that seen in matched metastatic deposits.  Work by Wang et al. (166)  has shown 
that the Rab25 gene is upregulated in a population of cells which can migrate 
away from a primary xenograft and invade into Matrigel plug, when compared 
with the general population of xenograft tumour cells. Extrapolating the results 
from this work gave rise to the hypothesis that metastatic deposits of breast 
cancer may demonstrate increased Rab25 protein expression when compared 
with the primary tumour.  The data shown in Table 4-4 show that this was the 
case in only 10 out of 41 (24%) cases and the majority of cases showed no change 
in Rab25 status or a decrease in Rab25 in the metastatic deposit when compared 
with the primary cancer. 
These data suggest that Rab25 expression does not sequentially increase or 
decrease when moving along the spectrum of malignancy from normal tissue to 
primary cancer and metastatic disease. Furthermore, there is no direct 
relationship between the Rab25 expression found between matched sets of 
samples of normal and primary tumour, and primary tumour and metastatic 
deposit. Indeed, given that Rab25 has been shown to be expressed in normal 
breast tissue, it cannot be considered to be a cancer specific marker in the 
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sense that Rab25 expression is not a hallmark of cancer tissue when compared 
with normal tissue. 
When interpreting these results, the small sample size should be borne in mind. 
However, the experiment contained sufficient numbers for the experiment to be 
adequately powered to detect a statistically significant difference if one was 
present. In addition, the clinical detail available was limited, for example no 
information was available on the clinical outcome or the oestrogen receptor 
status of the tumours. Even if this information had been available for these 35 
samples, there would not have been sufficient numbers of ER-positive and ER-
negative tumours for the experiment to be adequately powered for subgroup 
analysis.  On this basis, ER staining was not undertaken on this cohort and 
therefore it was not possible to investigate further the findings of Cheng et al., 
who demonstrated that the loss of Rab25 in breast cancer when compared to 
matched normal tissue was seen predominantly in ER negative cancers, rather 
than ER positive cancers (112).  In order to robustly investigate this hypothesis is 
was necessary to use a much larger cohort with associated good quality clinical 
data.   
The West of Scotland Breast Cancer TMA was originally constructed to 
investigate the relationship between oestrogen receptor status and clinical 
outcome and a number of studies using the TMA have been published (167).  
Clinical data including tumour size, grade, ER status, Her2 status and lymph 
node status and breast cancer related survival time of the patients was available 
for investigation. 
The observation that there was no significant difference in clinical outcome 
between patients with tumours with Grade 2 Rab25 staining and those with 
Grade 3 staining, and the subsequent combining of these two groups into a single 
“Rab25 positive” cohort, is in keeping with the method adopted for other 
clinically relevant prognostic indicators, such as HER2 where 0, 1+ and 2+ are 
deemed “HER2 negative”, while those tumours which are 3+ are deemed positive 
for the purposes of treatment with trastuzumab (50).  
When the importance of the oestrogen receptor status of breast cancer was first 
discovered, the percentage of the tumour sample which stained positive for the 
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oestrogen receptor was reported routinely in clinical practice as described in the 
scoring systems discussed above. Subsequent investigation demonstrated that, in 
terms of clinical relevance, tumours could be classified as either ER positive 
(greater than 10% of visualised cells stain positive for oestrogen receptor) or ER 
negative (less than 10% of visualised cells stain positive for oestrogen receptor) 
(168).  The approach adopted for the data presented here is therefore not 
without precedent in the investigation of breast cancer. 
The mechanisms by which Rab25 contributes to deceased breast cancer related 
survival in patients with ER negative breast cancer are not clear. One potential 
explanation is that Rab25 expression may be different between true luminal 
epithelial cancers and basal-like cancers.  If Rab25 expression is lower in the 
myoepithelial cells from which basal-like cancers arise, it may be hypothesised 
that this would be reflected in lower expression in basal tumours. If the ER -
negative/Rab25 group is composed of mainly basal-like cancers and the ER – 
negative/Rab25 group is composed of ER negative non-basal cancers, then the 
results presented here may simply reflect the well documented differential in 
survival between these two groups.  
The clinical surrogate of basal-like breast cancer is the triple negative 
phenotype, as discussed in 1.3.2.  While the ER and HER2 status of the tumours 
in this cohort are known, the PR status is not. However, as outlined in 1.4.2 only 
1-5% of cancers are documented as having the ER-negative/PR – positive 
phenotype, and hence one can assume that only 1-5% of the cases include in the 
analysis presented here will be PR positive.  Given the magnitude of difference 
in breast cancer related survival demonstrated, it would seem unlikely that 
knowledge of the PR status of these tumours would add any useful additional 
information. 
Further work investigating expression profile of EGFR and cytokeratin expression 
in this cohort to identify the proportion of cancers which are truly basal is 
warranted, and then the effect of Rab25 status on survival may be clearer.   In 
addition, further investigation of Rab25 expression in the different cellular 
components of the normal breast will be of value in determining whether loss of 
Rab25 expression is simply a reflection of the true tumour type or whether 
Rab25 is exerting a significant effect on survival. 
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Investigation of EGFR expression may reveal more information than simply the 
pathological subtype of the tumours. As discussed in 1.4.6, it has been 
hypothesised that Rab25 may be involved in an RCP/α5β1 integrin/EGFR complex 
and perturbation of this interaction by loss of Rab25 may affect trafficking of 
the EGFR receptor within cells. There is a significant inverse relationship 
between ER expression and EGFR expression (169), and further investigation of 
the interplay between EGFR, ER and Rab25 expression will be of value in 
determining if Rab25 plays a clinically significant role in the survival of patients 
with ER negative cancer and if Rab25 expression represents a potential 
therapeutic target.  
The relationship between Rab25 expression and β1 integrin will be explored in 
more detail in Chapter 5. 
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5 The effect of siRNA knockdown of Rab25 
expression in MCF7 breast cancer cells. 
5.1 Introduction 
5.1.1 MCF7 cells as a model for studying the cell biology of breast 
cancer 
The MCF7 breast cancer cell line is one of the most commonly used cell lines in 
the laboratory investigation of breast cancer. The cell line was derived in 1970 
from cells obtained from a pleural effusion of a patient with metastatic breast 
cancer (170).  The cells express both oestrogen and progesterone receptors, but 
lack expression of HER2 (171),  and the discovery of expression of steroid 
hormone receptors in this cell line has facilitated extensive investigation of 
cellular signalling in response to oestrogenic stimulation. Indeed, growth of 
MCF7 cells in tissue culture is greatly enhanced by the presence  of oestrogenic 
compounds in the serum used in tissue culture medium (172) and in vivo 
xenograft work using MCF7 cells requires additional supplementation of 
exogenous oestrogen to promote xenograft growth (173). 
MCF7 cells express surface β1 integrin, but at lower levels than that seen in 
human breast epithelial cells (174), and have also been shown to express β4 
integrin (175) and the α2, α3 and α6 subunits (175, 176).  
5.1.2 siRNA as a tool for the study of cell biology 
In order to assess the effect of knockdown of Rab25 expression in MCF7 cells it 
was necessary to design an appropriate RNA interference (RNAi) strategy. The 
laboratory exploitation of the endogenous intracellular RNA interference system, 
also termed post-translational gene silencing, results in transient or stable 
knockdown of expression of the protein of interest. The endogenous RNA 
pathway is initiated by the Dicer enzyme, which cleaves long double-stranded 
RNA fragments into shorter sections approximately 20 nucleotides in length. The 
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structure of the resulting fragments is well defined, with a 3’ overhang of 2 
nucleotides on each strand (177).  
Once the short RNA strands have been cleaved, one strand of each fragment, 
called the guide strand, associates with the RNA-inducing silencing complex 
(RISC) (178). This multi-protein complex uses the RNA strand as a template to 
identify complementary mRNA which, once identified, is degraded by the 
activation of the Argonaute proteins into 20-23 nucleotide sections, suggesting 
that the siRNA strand is targeting the specific cleavage of the mRNA molecule 
(179). The degradation of mRNA results in significantly reduced levels of mRNA 
template available for protein translation, in effect switching off the gene 
effect.  
Exploitation of this process to investigate the in vitro effect of silencing a 
particular gene of interest can be achieved by the transfection of exogenous 
siRNA. Transfection with appropriately designed synthetic oligonucleotides 
mimicking the 21-23 nucleotide fragments produced by Dicer, results in a knock 
down of protein expression (180). However, this effect is transient and not 
transmitted to daughter cells. 
For stable knockdown to be achieved, it is necessary to transfect a vector 
containing an expression sequence of a single RNA transcript which is designed 
as two palindromic 20-23 nucleotide sequences joined by a tightly structured 
hairpin loop, termed short hairpin RNA. Expression of this sequence in usually 
under the control of the H1 or U6 RNA polymerase III promoters, to ensure the 
sequence is always expressed. Once expressed, the hairpin is processed by Dicer 
and the resulting siRNA acts as described above (181).  Such vectors are usually 
transmitted to daughter cells, resulting in a population of cells stably expressing 
the shRNA with consequent knockdown of protein expression. 
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5.2 Results 
5.2.1 Rab25 protein expression is stably knocked down in MCF7 
cells 
To investigate the effect of Rab25 knockdown on MCF7 cells it was first 
necessary to confirm the expression of Rab25 in this cell line. Western blotting 
of lysate of the MCF7 breast cancer cell line using the anti-Rab25 antibody 
produced a band of the predicted molecular weight, confirming that this cell 
line expressed Rab25. Figure 5-1 confirms the presence of a band at 25kD in both 
A2780-Rab25 cells and MCF7 cells. As described in Chapter 3, the molecular 
weight of Rab25 in cells with endogenous expression of Rab25 is slightly smaller 
than the HA-tagged Rab25 produced by ectopic expression in A2780-Rab25 cells, 
and this is confirmed to be the case in MCF7 cells also. 
5.2.2 Stable knock down of Rab25 in MCF7 cells 
To investigate the effect of Rab25 knockdown in MCF7 cells it was necessary to 
design a short hairpin vector. Following confirmation of the hairpin sequence, 
MCF7 cells were transfected with either the pSUPERGFP-Neo Rab25 expression 
vector or a scramble control pSUPERGFP-NEO vector using Lipofectamine.   The 
pSUPERGFP-Neo expression vector contained a GFP expression cassette and a 
cassette conferring neomycin resistance. Following transfection, cells were 
selected for the presence of the vector by growing the transfected cells in media 
to which neomycin had been added. When neomycin-resistant colonies had 
become established, 24 colonies of each of the pSUPERGFP-Neo Rab25 and 
pSUPERGFP-Neo control transfected cells were screened for the presence of the 
vector by fluorescence imaging. Those not exhibiting strong GFP expression were 
discarded, and the remaining colonies were screened for the expression of Rab25 
by Western blotting.  From the colonies with demonstrable knockdown of Rab25 
expression by Western blotting, three colonies were selected for use in 
subsequent experiments, Rab25 KD clone 7, Rab25KD clone 10 and Rab25 KD 
clone 11.  Of the scramble MCF7 control colonies, two were selected, MCF7 
control clone 9 and MCF7 control clone 12.  
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Western blotting of lysates from the selected clones MCF7 Rab25 KD clones 7, 10 
and 11 and MCF7 Control clones 9 and 12, when incubated with anti-Rab25 
antibody, confirmed the presence of a 25kD band consistent with the expression 
of Rab25. Figure 5-2 clearly shows a diminution of the signal in the clones stably 
expressing the pSUPERGFP-Neo vector when compared with the cells expressing 
the scramble control vector, confirming knockdown of Rab25 protein expression 
in the Rab25 KD clones. 
5.2.3 Knockdown of Rab25 protein expression does not affect 
growth rate or colony formation in MCF7 cells  
Prior to undertaking any experiments investigating the functional effect of 
knockdown of Rab25 protein expression, it was necessary to ascertain if Rab25 
knockdown (Rab25KD) had any effect on the growth characteristics of MCF7 
cells. Once it had been confirmed that the three colonies of MCF7 cells could 
maintain expression of the Rab25KD hairpin vector over time and in the absence 
of neomycin pressure, the effect of knockdown of Rab25 expression on the 
growth of these cells was investigated. Standard growth rate curves for the 
Rab25KD clones and MCF7 control clones were performed and the ability of the 
clones to form colonies in soft agar was investigated. Figure 5-3 illustrates the 
growth rates of MCF7 Rab25 KD and MCF7 control clones when grown in standard 
medium over a period of 8 days.  All Rab25 KD clones and MCF7 control clones 
grew at a very similar rate, and hence the mean growth rate for each condition 
is shown for ease of presentation.  There was no difference between the growth 
rate of MCF7 Rab25 KD cells and MCF7 control cells under these conditions. 
The ability of MCF7 cells to form colonies when grown in soft agar was also 
unaffected by the knockdown of Rab25, when compared with MCF7 control cell 
clones. Figure 5-4 confirms that the mean total colony number identified was 
similar in MCF7 Rab25 KD and MCF7 control clones and in addition, the mean 
number of large colonies (colonies greater than 62.5 µm2) formed was 
unaffected by the knockdown of Rab25 expression. 
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1 ATGGGGAATG GAACTGAGGA AGATTATAAC TTTGTCTTCA AGGTGGTGCT GATCGGCGAA
61 TCAGGTGTGG GGAAGACCAA TCTACTCTCC CGATTCACGC GCAATGAGTT CAGCCACGAC
121 AGCCGCACCA CCATCGGGGT TGAGTTCTCC ACCCGCACTG TGATGTTGGG CACCGCTGCT
181 GTCAAGGCTC AGATCTGGGA CACAGCTGGC CTGGAGCGGT ACCGAGCCAT CACCTCGGCG
241 TACTATCGTG GTGCAGTGGG GGCCCTCCTG GTGTTTGACC TAACCAAGCA CCAGACCTAT
301 GCTGTGGTGG AGCGATGGCT GAAGGAGCTC TATGACCATG CTGAAGCCAC GATCGTCGTC
361 ATGCTCGTGG GTAACAAAAG TGACCTCAGC CAGGCCCGGG AAGTGCCCAC TGAGGAGGCC
421 CGAATGTTCG CTGAAAACAA TGGACTGCTC TTCCTGGAGA CCTCAGCCCT GGACTCTACC
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Figure 5-1 Strategy for stable knockdown of Rab25 in MCF7 cells. 
A Western blots of lysates of A2780-DNA3, A2780-Rab25 and MCF7 cells incubated with anti- 
Rab25 antibody (top panel) and anti- β-actin antibody (bottom panel.) B Schematic diagram of 
pSUPERGFP-Neo expression vector. C Rab25 DNA sequence – hairpin target sequence 
highlighted in red. D Target sequence of scramble control and Rab25 hairpin vector. 
124 
25
50
Ra
b2
5 
KD
 
Cl
on
e 
7
Ra
b2
5 
KD
 
Cl
on
e 
10
Ra
b2
5 
KD
 
Cl
on
e 
11
Co
nt
ro
l 
Cl
on
e 
9
Co
nt
ro
l
Cl
on
e 
12
Blot:Rab25
Blot:β-actin
 
Figure 5-2 Assessment of Rab25 knockdown in MCF7 cells.  
Lysates of MCF7 knockdown and control clones were Western blotted for Rab25 (top panel) β-
actin (bottom panel)(n=3).  
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Figure 5-3 Effect of Rab25 knockdown on the proliferation rate of MCF7 cells. Cell 
proliferation curves for MCF7 Rab25 KD and Control cells 
(A) Plot for Rab25KD clones 7, 10 and 11 and control clones 9 and 12. p value for one sided 
ANOVA shown (B) Rab25 and control clones grew at the same rate and the mean growth rate for 
each condition was calculated. Curves plotted are mean ±SEM of three colonies of KD and control 
cells. p value for students’ t-test shown. Representative plot shown (n=3) 
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MCF 7 Growth in soft agar - Total Colony number
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Figure 5-4 Effect of Rab25 knockdown on colony formation in MCF7 cells. 
A Total number of colonies present per 6.25mm2 of soft agar. B Total number of colonies greater 
than 62.5µm2 present per 6.25mm2 of soft agar. Results are mean ± SEM of 3 experiments. p 
values for one way ANOVA shown. 
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5.2.4 Knockdown of Rab25 protein expression increases the rate 
of wound healing in MCF7 cells 
Scratch wound assays were performed to assess the effect of the knockdown of 
Rab25 expression on migration of MCF7 cells on plastic. Figure 5-5 shows the 
mean net displacement of the wound edge over a 16 hour timeframe for MCF7 
Rab25 KD and MCF7 control clones.  These data indicate that the net 
displacement of the wound edge was significantly greater in MCF7 Rab25 KD 
clones when compared with MCF7 control clones. 
 
5.2.5 Knockdown of Rab25 protein expression increases total 
surface and intracellular β1 integrin protein levels in MCF7 
cells 
Having demonstrated that MCF7 Rab25 KD cells migrate to a greater extent into 
a wound than MCF7 control cells, the hypothesis was generated that this 
observation may be related to integrin expression.  To investigate the 
relationship between Rab25 and β1 integrin protein expression in the MCF7 
Rab25KD and stable clones, Western blotting for total β1 integrin levels was 
performed. In addition, surface labelling of β1 integrin and subsequent 
immunoprecipitation of the β1 protein was performed to investigate the relative 
quantity of Rab25 protein at the surface of the cell. In brief, β1 integrin present 
at the cell surface was labelled with an NHS-SS-Biotin label.  Following cell lysis, 
immunoprecipitation using β1 integrin antibody and Western blotting, the blot 
was incubated with streptavadin-HRP to produce a signal.  
Figure 5-6 shows a Western blot of lysates of the MCF7 Rab25 KD and MCF7 
control clones incubated with anti-β1 integrin antibody and anti-Rab25 antibody.  
This blot shows a significant increase in β1 integrin levels in the Rab25 KD cells 
compared with MCF7 control cells, suggesting an inverse relationship between 
Rab25 protein levels and total β1 integrin levels. Furthermore, the precursor 
form of β1 integrin (which is approximately 20kDa smaller than the mature, 120 
kDa form of β1) is present in similar proportions to mature β1 protein 
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irrespective of Rab25 status, suggesting that knockdown of Rab25 does not 
enhance the conversion of proform β1 integrin to mature β1 integrin.  
Furthermore, Figure 5-6 demonstrates that, while there is a small increase in the 
surface levels of β1 integrin in the MCF7 Rab25 KD cells when compared with 
MCF7 control cells, this increase is not in the same proportion as that seen in 
total β1 protein.  
5.2.6 Increased β1 integrin levels in MCF7 Rab25 KD cells are not 
a consequence of increased transcription 
Quantitative RT-PCR was performed to investigate whether knockdown of Rab25 
protein expression affected β1 integrin mRNA levels.  It was necessary to design 
and validate 4 sets of qRT-PCR primers; primers designed to amplify a product 
from β1 integrin and Rab25 and the housekeeping genes β-actin and GAPHD. 
Prior to performing qRT-PCR, it was necessary to ensure that each primer pair 
amplified a single product, that they amplified the correct product in a linear 
fashion over a range of concentrations of cDNA and did not amplify genomic 
DNA. Once the qRT-PCR primers had been validated and the optimal conditions 
for qRT-PCR had been confirmed, qRT-PCR to investigate the mRNA levels of 
Rab25 and β1 integrin in the Rab25 KD and MCF7 control clones was performed. 
Details of how the primer properties were confirmed and qRT-PCR was 
performed are given in section 2.6.5.  
Figure 5-7 confirms that the selected primers for Rab25, β1 integrin, β-actin and 
GAPDH amplified PCR products in a linear fashion over a wide range of 
concentration of cDNA and shows details of the efficiency of the primers. 
Confirmation that the primers amplified a single qRT-PCR product is shown in 
Figure 5-8. 
Having validated the qRT-PCR primers sets, qRT-PCR for Rab25 and β1 integrin 
and the housekeeping genes β-actin and GAPDH was undertaken using RNA 
extracted from MCF7 Rab25 KD clone 10 and MCF7 Control clone 9. This 
confirmed that the Rab25 mRNA levels were lower in the MCF7 Rab25 KD cells 
compared with MCF7 control cells, in keeping with a functioning Rab25-targeted 
short hairpin vector.  In contrast, there was no significant difference in the 
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mRNA levels for β1 integrin between MCF7 Rab25 KD and MCF7 control cells and 
these data are illustrated in Figure 5-9. 
 
 
 
130 
MCF 7 Wound Healing Assay
0
50
100
150
200
250
300
350
400
Ra
b2
5 
KD
Cl
on
e 
10
Ra
b2
5 
KD
Cl
on
e 
11
Co
nt
ro
l
Cl
on
e 
9
Co
nt
ro
l
Cl
on
e 
12
N
et
 d
is
pl
ac
em
en
t 
(u
m
)
MCF7 KD Clone 10 Control Clone 12
t = 0 hrs
t = 16hrs
314 µm 109 µm
A
B
p=0.015
 
Figure 5-5 Effect of Rab25 knockdown on wound healing of MCF7 cells. 
A Representative images of wound edge at time 0 and 16 hours. B Net displacement of wound 
edge over 16 hours. Results are mean ± SEM of three experiments. p value for one way ANOVA 
shown 
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Figure 5-6 Effect of Rab25 knockdown on β1-integrin levels in MCF7 cells. 
A  Cell surface labelling of β1 integrin.  Lysates of MCF7 Rab25 KD and Control clones surface 
labelled with –ss-biotin and immunoprecipitated with β1 integrin antibody (left panel) and RG-16 
(right panel) were Western blotted and blots incubated with streptavidin-HRP (n=2). B Whole cell 
lysates of MCF7 Rab25 KD and Control clones prepared for immunoprecipitation above were 
Western blotted for β1 integrin (top panel), β-actin (middle panel) and Rab25 (bottom panel) (n=3). 
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Figure 5-7 Validation of quantitative RT-PCR primers. 
A Standard concentration curve for Rab25 qRT-PCR primers. B Standard concentration curve for 
β1 integrin qRT-PCR primers. C Standard concentration curve for β-actin qRT-PCR primers. D 
Standard concentration curve for GAPDHqRT-PCR primers. E Primer efficiency. 
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Figure 5-8 Quantitative RT-PCR primers produce a single product. 
A RT-PCR product from MCF7-Rab25 KD and Control cells using Rab25, β1 integrin, β-actin and 
GAPDH primers. B Melting curves for Rab25, β1 integrin, β-actin and GAPDH primers. 
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Figure 5-9 Quantitative RT-PCR of Rab25 and β1 integrin levels in Rab25 knockdown and 
control cells. 
A Fold change in Rab25 mRNA levels in MCF7 Rab25 knockdown clone 10 and MCF7 Control 
clone 9 normalised for β-actin and GAPDH. B Fold change in β1 integrin levels in MCF7 Rab25 
knockdown clone 10 and MCF7 Control clone 9 normalised for β-actin and GAPDH. Results are 
mean ± SEM of 9 experiments.
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5.3 Discussion 
At the commencement of this project, the majority of the published literature 
investigating the role of Rab25 in cancer focussed on the upregulation or 
overexpression of Rab25 in cancer tissue or cell culture systems. As discussed in 
sections 1.6 and 1.7, these data suggested that overexpression of Rab25 in 
breast and ovarian cancer tissue was associated with a poorer clinical outcome 
(107) and that forced expression of Rab25 in an in-vitro system promoted an 
invasive mode of migration in these cells (119). As previously discussed, the 
published studies which have investigated what effect the loss of Rab25 may 
have on cellular function are somewhat contradictory in nature (110, 111). The 
aim of the work presented here was to further inform the debate on the effect 
of the loss of Rab25 protein expression in cancer. 
The data presented here confirm that Rab25 protein expression in the MCF7 
breast cancer cell line was successfully abrogated by the stable transfection of 
the pSUPERGFP-Neo vector containing the short hairpin sequence targeted 
against Rab25.  The level of Rab25 knockdown was maintained with increasing 
passage number of cells and following freezing and thawing of cells (data not 
shown) 
Once the stable MCF7 Rab25 knockdown and control cell lines were established, 
it was possible to establish whether the growth characteristics of MCF7 cells 
were altered by the knockdown of Rab25 protein expression.  The data 
presented here suggest that loss of Rab25 protein expression has no effect on 
the growth rate of MCF7 cells, nor on the ability of MCF7 cells to form colonies 
in soft agar.   
These finding are in direct contrast with the findings of Fan et al, who describe a 
significantly decreased cellular proliferation rate, both in vitro and in vivo, of 
A2780 ovarian cancer cells stably transfected with a short hairpin expression 
vector targeted against Rab25 similar to the one described in this work (110).   It 
is of note that the A2780-DNA3 cells used in this work, as described in Chapter 3, 
do not show evidence of Rab25 expression by either RT-PCR or Western blotting 
with an anti-Rab25 antibody. It therefore remains unclear whether, as a general 
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principle, proliferation of cells is dependent upon Rab25 function or whether 
these observations are cell type specific. Further work to investigate the effect 
of Rab25 loss on the proliferation of other cell lines is needed. 
The observation, illustrated in Figure 5-5, that MCF7 Rab25 KD cells can migrate 
to heal a scratch wound at a faster rate than MCF7 control cells, suggests that 
the function of Rab25 in cancer progression may be related to the ability of 
these cells to migrate.  Caswell et al. have demonstrated that Rab25 interacts 
directly and specifically with the β1 cytoplasmic tail of the α5β1 integrin, and 
overexpression of Rab25 in A2780 ovarian cancer cells promotes an invasive 
mode of cell migration in Matrigel inverse invasion assays (119). Again, the data 
presented here conflict with these published findings, as knockdown of Rab25 
protein expression, rather than overexpression, resulted in an increased rate of 
migration in MCF7 cells. However, it should be noted that the effect described 
by Caswell et al was seen when cells were grown in Matrigel, but not apparent 
when the same cells were plated on plastic, giving rise to the suggestion that 
the effect of Rab25 expression may be dependent on the not only on the cell 
type, but also on the cell culture conditions.  Multiple attempts to investigate 
the ability of the MCF7 Rab25 KD and control cells to invade into Matrigel or 
collagen plugs were made but were unsuccessful, as neither set of clones could 
invade the matrix to any demonstrable degree.  Hence, no conclusions can be 
drawn with regard to the effect of loss of Rab25 on invasiveness of MCF7 cells 
from the data presented here. 
The investigation into the β1 integrin status of the MCF7 Rab25 KD and control 
cells resulted directly from the observation that MCF7 Rab25 KD cells migrate 
more quickly than control cells to heal a scratch wound.  Figure 5-6 clearly 
shows that total β1 integrin levels are significantly higher in MCF7 Rab25 KD cells 
when compared with controls.  To further investigate the hypothesis that 
knockdown of Rab25 protein expression in MCF7 cells results directly in an 
increase in total β1 integrin levels, preliminary Rab25 rescue experiments were 
performed. A cherry-tagged Rab25 protein expression vector was transiently 
transfected into MCF7 Rab25 KD cells to restore the expression of Rab25.  As 
shown in supplementary Figure S-1, Western blotting and incubation with anti-
Rab25 antibody of lysates of these cells at 24, 48 and 72 hours confirmed the 
presence of a band at 50kD, in keeping with the predicted molecular weight of 
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Ch-Rab25, indicating successful rescue of Rab25 expression.  Incubation of the 
same blot with anti-β1 integrin antibody showed a reciprocal decrease in β1 
integrin expression with re-expression of Rab25.  This experiment needs to be 
repeated to confirm this finding, but this early evidence intimates an inverse 
relationship between Rab25 and β1 integrin expression in MCF7 cells. 
While total β1 integrin levels were significantly raised in MCF7 Rab25 KD cells 
compared with control cells, this magnitude of difference was not maintained at 
the cell surface, suggesting that the majority of the additional β1 integrin in the 
MCF7 Rab25 KD cells was present intracellularly. However, although the 
difference in surface expression of β1 integrin between MCF7 Rab25 KD and 
control cells was small, there was a demonstrable increase in β1 integrin 
expression in the MCF7 Rab25 KD cells which may be sufficient to contribute to 
the enhanced wound healing ability observed. 
To assess whether the increase in β1 integrin observed in MCF7 Rab25 KD cells 
was as a result of transcriptional upregulation,  qRT-PCR was performed to 
quantify the mRNA levels of Rab25 and β1 integrin in both MCF7 Rab25 KD and 
control cells. This confirmed that, while the Rab25 mRNA levels were 
significantly reduced in MCF7 Rab25 KD cells compared with controls, as would 
be expected with in the presence of a short hairpin expression vector targeted 
against Rab25, there was no significant difference in β1 integrin mRNA levels, 
despite the obvious difference in protein levels demonstrated on Western 
blotting. 
In summary, the stable MCF7 Rab25 knockdown cell line did not exhibit any 
demonstrable difference in growth rate or ability to form colonies in soft agar 
when compared with MCF7 cells transfected with a scramble control vector.  
However, the MCF7 Rab25 KD cells did migrate to heal a scratch wound at a 
faster rate than controls. The observation that the Rab25 knockdown cells 
exhibit a greater total and surface level of β1 integrin protein when compared 
with controls, may indicate a mechanism by which this increased migratory 
ability occurs, but more work is needed to investigate this hypothesis further.  
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6 General Discussion 
The Rab GTPase family of proteins are the master regulators of intracellular 
transport, coordinating vesicular trafficking of both endogenous and exogenous 
pathways. Rab proteins are ubiquitously expressed in all mammalian cells, but 
some are expressed in specific cell types, such as Rab25 which is confined to 
epithelial cells.  
Investigation into the role that Rab proteins play in cancer is relatively 
immature, and as such the data that are available are often contradictory. On 
commencing this project, there were published data to suggest that both over 
expression and loss of Rab25 in breast tumours may have a negative impact on 
the survival of patients.  The aim of this work was to further inform the debate 
of the role of Rab25 in breast cancer. 
The production and validation of a robust anti-Rab25 antibody was essential 
prior to undertaking the further work on human tissue and Rab25 knockdown cell 
lines. The results presented in Chapter 3 confirm, as far as possible, that the 
purified polyclonal antibody could reliably detect Rab25 in a number of 
laboratory applications. It was therefore possible to proceed to investigation of 
Rab25 in clinical samples and in cell culture work. 
The results presented in Chapter 4 suggest that loss of Rab25 expression in 
patients with oestrogen receptor negative breast cancer is associated with 
significantly reduced breast cancer related survival, when compared with those 
patients who have cancers which express Rab25. Furthermore, survival of 
patients with ER negative and HER2 negative breast cancer was significantly 
poorer when the tumour had also lost expression of Rab25, compared with ER 
negative, HER2 negative cancers which had retained Rab25 expression.  
As discussed in Chapter 4, it was not possible to ascertain if the tumour samples 
which were ER negative/HER2 negative represented cancers which were truly 
basal, and further investigation to confirm the status of these tumour is 
required.  Confirming the PR status of these tumours is unlikely to add 
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significant further information, and immunohistochemical staining of the TMA for 
basal cytokertains and EGFR would be the most obvious next step. 
If further investigation revealed that Rab25 loss was seen exclusively in basal 
cancers, it would then be necessary to investigate if the loss of Rab25 is purely a 
reflection of the Rab25 status of the distinct cells of origin of luminal and basal 
cancers. At the present time it is not known if Rab25 expression in normal breast 
luminal epithelial cells is similar to that in breast myoepithelial cells and 
immunohistochemistry may not be sufficiently sensitive to distinguish 
differences in Rab25 expression between these two cellular subtypes. Further 
work using micro-dissection of the cells of interest may be required. 
The decision to investigate the effect of Rab25 loss in MCF7 cells was taken prior 
to the results from the TMA study being available. In retrospect, given the 
results obtained from the clinical study, that Rab25 loss appears to be associated 
with ER negative tumours, the choice of an ER negative cell line may have been 
advantageous. However, without the benefit of this knowledge, the MCF7 cell 
line was chosen as a well characterised cell line which expressed endogenous 
Rab25.  Further work to investigate the effect of Rab25 knockdown in an ER 
negative breast cancer cell line, or indeed re-expression of Rab25 in an ER 
negative cell line which does not express Rab25, may be helpful in establishing if 
the effects seen here are widely applicable or simply cell line specific. 
The data presented in Chapter 5 show that MCF7 Rab25 knockdown cells migrate 
to close a scratch wound at a faster rate, and that the Rab25 knockdown cells 
show increased total and surface β1 integrin protein levels, when compared with 
control MCF7 cells. It has been confirmed by qRT-PCR that the increase in β1 
integrin protein levels seen in MCF7 Rab25 KD cells was not as a consequence of 
increased transcriptional activity.  
One hypothesis to explain the rise in β1 integrin protein levels is that the 
increased intracellular levels of β1 integrin seen in MCF7 Rab25 KD cells may be 
as a result of impaired cellular degradation of the protein.  As previously 
described,  the work by Caswell et al (ref) has shown that Rab25 interacts with 
the β1 cytoplasmic tail of the α5β1 integrin dimer, promoting short loop 
recycling of the integrin to the cell surface.  If Rab25 is necessary for the 
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recycling of the β1 integrin, it can be hypothesised that in the absence of Rab25, 
the β1 integrin is unable to transit thought the cell to the correct compartment 
for degradation, leading to increased total cellular protein levels. It is unlikely 
that Rab25 is the only pathway by which β1 integrin is trafficked to the cell 
surface, and the increase in cellular protein levels of β1 integrin will make more 
β1 integrin available to other trafficking pathways and hence the small increase 
in surface β1 integrin levels might be explained.  Further work is required to 
examine this hypothesis more closely and to establish the mechanism by which 
knockdown of Rab25 expression results in the increase in intracellular β1 integrin 
protein levels.   
It would also be interesting to perform immunohistochemistry of the breast 
cancer TMA for β1 integrin, to ascertain if the inverse relationship between 
Rab25 and β1 integrin seen in the MCF7 KD cells is replicated in breast cancer 
tissue.  
 A further disadvantage of using the MCF7 cell line is that the cells do not invade 
in standard invasion assays and they do not form xenografts in nude mice in the 
absence of exogenous oestrogen supplementation.  The animal licensing 
applications in place in the Beatson Institute for Cancer Research at the time of 
this work did not permit exogenous oestrogen supplementation of nude mice. 
Xenografts using the MCF7 Rab25 KD and control cell were attempted without 
oestrogen supplements, but were unsuccessful. Further work to investigate the 
behaviour of MCF7 Rab25 KD cells in xenograft models, would help to establish if 
the loss of Rab25 has any effect on cell growth in vivo.  Knockdown of Rab25 in a 
cell line which can invade a matrix would also permit investigation of the effect 
of changes in growth conditions, such as the effect of exogenous factors such as 
EGF and β1 integrin inhibitory antibodies, on the ability of cells to invade. 
In conclusion, the work presented here suggests that the loss of Rab25 in 
patients with ER negative/Her2 negative breast cancers confers a negative 
effect on the survival of these patients. The mechanisms by which loss of Rab25 
in these patients results in an absolute reduction in survival of 4.2 years when 
compared with patients with ER negative/Her2 negative cancers which have 
retained expression of Rab25, is not yet clear. One hypothesis is that the loss of 
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Rab25 results in the perturbation of β1 integrin signalling within tumour cells, 
resulting in a more aggressive cancer.   
Given that Rab25 is an intracellular protein without surface expression, it would 
seem difficult, with current pharmacological methods, to envisage Rab25 as a 
direct therapeutic target. However, if further work on the effect of Rab25 loss 
confirms a demonstrable effect on downstream effectors such as β1 integrin or 
EGFR, then there may be indirect therapeutic targets which can be manipulated 
to improve the survival of this group of patients, for whom the outcome 
currently is poor. 
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Figure S-1 Effect of exogenous expression of Cherry-Rab25 on β1 integrin levels in MCF7 
cells. 
Western blots of cell lysates of MCF7 KD clones 7 and 10 transfected with Cherry-Rab25, 
incubated with anti-β1 integrin antibody (top panel), anti-Rab25 antibody (middle panel) and anti- β-
actin antibody (bottom panel). 
 
 
 
